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ABSTRACT 
Decoding the signaling of the D2R-2AR heteromer: relevance to schizophrenia 
By  
Miao Huang 
Advisor: Dr. Diomedes Logothetis 
 
         Schizophrenia is a severe mental disorder affecting ~1% of world population. Two G-
protein coupled receptors (GPCRs): Gi-coupled dopamine 2 receptor (D2R), and Gq-coupled 
serotonin 2A receptor (2AR), are targeted by the typical and atypical antipsychotic drugs to treat 
schizophrenia. These two receptors have been shown to co-localize in brain regions relevant to 
schizophrenia, including the ventral tegmental area (VTA), striatum, and prefrontal cortex 
(PFC). Studies in our lab characterized the integrated signaling of the D2R-2AR heteromer and 
found that both the Gi activity of D2R and the Gq activity of 2AR were potentiated in response to 
dopamine (DA) and serotonin (5-HT), whereas the potency of the typical antipsychotic drug 
(APD) haloperidol antagonizing Gi and Gq signaling was also enhanced. Using a peptide 
mimicking the transmembrane (TM) domain 5 of D2R, we showed disruption of the formation 
and function of the D2R-2AR heteromer in heterologous systems and ex vivo brain slices. Our 
functional and mutagenesis data suggested that D2R and 2AR heteromerize though a symmetric 
TM5,6-TM5,6 interface, and a network of Pi-Pi stacking interaction among eight conserved 
aromatic residues of D2R and 2AR may underlie the mechanism for the functional cross-talk 
between D2R and 2AR. Based on these results, we built a structural model for the D2R-2AR 
iv	
	
heteromer recapitulating its functional cross-talk characteristics. We are presently pursuing 
behavioral experiments to investigate the effectiveness of antipsychotic drugs on the function of 
the D2R-2AR heteromer in animal models of psychosis. Our overall study shows a dual role of 
the D2R-2AR heteromer in schizophrenia-associated psychosis and sheds light on the 
development of future therapeutic drugs for schizophrenia and other psychotic diseases. 
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Chapter 1. INTRODUCTION 
 
 
 
1.1 Schizophrenia and hypotheses 
 
         Schizophrenia is a debilitating mental disorder that affects approximately 1% of the world 
population. Symptoms are generally divided into three broad categories: positive symptoms 
(hallucinations, delusions, disorganized thoughts and behaviors), negative (social withdrawal, 
emotion flat, lack of interest), and cognitive (impaired working memory, attention deficits).1 
Schizophrenia is among the most costly mental disorders with annual costs exceeding 100 billion 
in the US alone.2 The etiology of schizophrenia remains unknown, although research suggests a 
combination of physical, genetic, psychological and environmental factors contributing to its 
causation.3-8 Among all the hypotheses of schizophrenia put forth, three have been studied the 
most: the dopamine, the glutamate, and the serotonin hypotheses.   
 
1.1.1 The dopamine hypothesis 
         The dopamine hypothesis is the classic and most established hypothesis of schizophrenia. It 
evolves from two observations: 1. Sustained exposure to D2R agonists or amphetamines (which 
increase dopamine release) induce schizophrenia-like positive symptoms. 2. Drugs which block 
dopamine or D2R function could reduce psychotic symptoms.9 In the dopamine hypothesis, 
hyperfunction of the DA mesolimbic pathway causes increased level of DA in the striatum, 
resulting in the positive symptoms of schizophrenia, whereas hypofunction of the DA 
	 2	
mesocortical pathway causes deficient release of DA in the prefrontal cortex (PFC), resulting in 
the negative and cognitive symptoms of schizophrenia (Figure 1.1).10 The dopamine hypothesis 
has been supported by evidence from postmortem, neuroimaging and clinical studies.  
          A large number of early postmortem studies have shown consistent findings of an increase 
in both striatal DA level and striatal D2R density in patients of schizophrenia.11-22 A recent study 
including 176 post mortem samples from patients of schizophrenia showed significantly 
decreased levels of D2R in PFC.23 The hypothesis that the level of D2R is altered in 
schizophrenia is also supported by genome-wide association study (GWAS) that have shown a 
clear association between the DRD2 gene and schizophrenia.24  
         The striatal D2R density has been extensively studied by PET and SPECT imaging. A 
major meta-analysis of 17 imaging studies revealed a small but significant elevation of striatal 
D2R in drug-naïve patients with schizophrenia.25-37 An increased striatal binding with D2R/D3R 
radiotracer [3H] spiperone but not [3H] raclopride has been reported in many studies.38-45 A more 
recent meta-analysis confirmed these observations, showing a small (d=0.26, p=0.049) elevation 
of D2R/D3R density in schizophrenia.46  
          Early clinical studies have shown correlations between low DA activity in the PFC, low 
cerebral blood flow to PFC and poor working memory tasks involving white matter in 
schizophrenia.47-48 Imaging studies with PET and SPECT have shown administration of D2R 
agonists occupied D2R and have beneficial effects on the PFC activation whereas administration 
of antipsychotic drugs crossed the blood-brain-barrier and blocked striatal D2R/D3R in vivo at 
clinically effective doses.49-61  
 
1.1.2 The glutamate hypothesis 
	 3	
          The role of glutamate and the N-methyl- D-aspartate (NMDA) receptor is based on two 
observations: 1. psychotomimetic drugs such as phencyclidine (PCP), dizocilpine (MK-801), and 
ketamine induce psychotic and schizophrenic symptoms by blocking neurotransmission at 
NMDA glutamate receptors;62 2. agents that stimulate NMDA receptor-mediated 
neurotransmission have shown encouraging results in preclinical studies. 62 In the glutamate 
hypothesis, hypofunction of glutamate receptor in the cortex causes schizophrenia-like 
symptoms and links to downstream dopamine networks.63,64 
           The glutamate hypothesis is supported by a number of studies. Early postmortem studies 
showed reduced NMDAR1 subunit density in the superior frontal and temporal cortex.65,66 
Proton Magnetic Resonance Spectroscopy (1H-MRS) studies showed reduced cortical glutamate 
levels and elevated glutamine:glutamate (Gln/Glu) ratio in the anterior cingulate cortex found in 
patients with chronic schizophrenia.65-72 Consistent morphological alterations were observed in 
dendrites of glutamatergic neurons in the cerebral cortex of schizophrenic subjects.73 Neurotoxic 
changes in cortical brain regions were observed in animals given NMDA receptor antagonists, 
which resembled the reductions in brain volume observed in schizophrenic subjects.74 NMDA 
receptor antagonists have been shown to reduce cortical GABAergic interneuron function, alter 
the prefrontal DA neuron firing patterns, and increase DA release to a challenge such as 
amphetamine.75-80 Activation of mGluR2/3 has been shown to reverse NMDA receptor 
antagonist-induced cortical neuronal injury and NMDA receptor hypofunction in PFC.81,82 
           Integrating the glutamate and dopamine hypotheses produces a more thorough theory 
underlying the mechanism of schizophrenia: a deficit in cortical glutamate or hypofunctional 
NMDA receptors on GABA interneurons in the PFC cause overactive downstream glutamate 
release by glutamate neurons projecting from PFC to VTA, which lead to hyperfunctional DA 
	 4	
mesolimbic pathway and hypofunctional DA mesocortical pathway, resulting in schizophrenic 
symptoms.64  
 
1.1.3 The serotonin hypothesis 
          The role of serotonin (5-HT) and 5-HT2AR (2AR) in schizophrenia originates from two 
observations: 1. atypical antipsychotics have highest affinity for 2AR and block the 
schizophrenia-like psychotic effects of serotonergic hallucinogens such as LSD;83 2. postmortem 
studies have found up-regulated levels of 2AR in the cortical regions of young untreated 
schizophrenic subjects.84 In the serotonin hypothesis, hyperfunction of 2AR in the cortex causes 
schizophrenia-like symptoms and links to downstream dopamine networks.64, 85  
          The serotonin hypothesis is supported by a series of studies and evidence. Psychedelic 
drugs such as psilocybin and lysergic acid diethylamide (LSD) induce schizophrenia-like 
psychosis through excessive 2AR activation.86-89 Psilocybin produces activation in the prefrontal 
cortex and produces hyperfrontality.90,91 Atypical APDs block the serotonin and glutamate 
release in PFC and reverse the cellular responses produced by PCP-like drugs in cortical 
pyramidal neurons.92-94 2AR at the cortical regions mediates the response induced by LSD-like 
hallucinogens.95,96 Increased levels of 2AR have been found in the temporal cortex of patients 
with visual hallucinations.97 2AR in the cortex has been found to modulate the activation of 
mGlu2/3 receptor and glutamate release from cortex to VTA.98 The potential role of 2AR in 
mediating the behavioral responses induced by NMDA antagonism is illustrated by PCP models 
(Figure 1.2).98 2AR in the medial prefrontal cortex controls the excitability of VTA dopamine 
neurons.99,100 
	 5	
         The studies and evidence for the serotonin hypothesis have developed it to a 
comprehensive theory for schizophrenia in which the role of dopamine, glutamate and serotonin 
are linked. In this theory, excess serotonin, upregulated 2AR, or psychedelic hallucinogens could 
all cause hyperactivation of 2AR on glutamatergic neurons in PFC, which leads to glutamate 
release from PFC to VTA. Excessive glutamate in VTA causes hyperactivity of DA mesolimbic 
pathway and hypoactivity of DA mesocortical pathway, resulting in schizophrenic symptoms 
(Figure 1.3).64,85 
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1.2 Antipsychotic drugs 
 
 
        Consistent with the dopamine, serotonin and glutamate hypotheses of schizophrenia, three 
types of antipsychotic drugs have been developed to treat schizophrenia and reduce psychosis.  
        Typical antipsychotic drugs (APDs) (e.g. haloperidol, loxapine) are high-affinity 
antagonists of D2R.101 They function though blocking the D2R-Gi signaling pathway and thereby 
reduce the hyperdopaminergic mesolimbic pathway and improve the positive symptoms of 
schizophrenia. While effective against positive symptoms, typical APDs demonstrate limited 
efficacy against negative symptoms and cognitive impairments. Moreover, these drugs are 
associated with a number of side effects including extrapyramidal symptoms (EPS), 
hyperprolactinemia, and obesity.102  
         Atypical APDs (e.g., clozapine, pimavanserin) differ pharmacologically from the typical 
APDs in that they possess higher affinity to 2AR and low affinity to D2R.103,104 They antagonize 
the 2AR-Gq signaling pathway and are effective in treating all three symptoms of schizophrenia, 
though the efficacy against negative and cognitive symptoms is only modest.104 Atypical APDs 
have less potential to induce EPS or hyperprolactinemia, but they are also associated with side 
effects, usually metabolic problems including weight gain and diabetes.105 In a meta-analysis of 
randomized controlled trials with 2522 participants, no significant differences between typical 
APDs and atypical APDs were found for effect on symptoms or discontinuation rates; typical 
APDs caused more EPS whereas atypical APDs caused more weight gain.106  
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          A third class of APDs (e.g., LY379268, RG1678), involve the agents that stimulate or 
improve the function of glutamate receptors. Ly3792768, an agonist of mGluR2/3, rescued 
NMDA and GABAA activity and reduces psychotic behavior in animal models.107 RG1678, a 
drug currently in Phase II trials, increased NMDA receptor function via inhibition of type 1 
glycine transporters (GlyT1).108 SAR218645, an mGluR2 positive allosteric modulator (PAM), 
improved memory and attention deficits in models of cognitive symptoms.109  
           Despite the availability of several typical and atypical APDs, fewer than 35% of people 
with schizophrenia showed complete remission.110 20%~30% of people diagnosed with 
schizophrenia do not respond to any antipsychotic therapy. 111 Novel therapeutics with enhanced 
efficacy and reduced side effects are needed.  
 
 
 
 
 
 
 
 
 
	 8	
1.3 The dopamine system 
 
1.3.1 Dopamine in the brain 
         Dopamine (DA) is synthesized from the amino acid tyrosine; tyrosine transported to DA 
neurons is converted to the direct precursor L-DOPA and decarboxylated to DA. DA is 
distributed in the brain through five DA pathways, among which two are most important and 
associated with schizophrenia and psychosis: the mesolimbic pathway, which drives DA from 
VTA to striatum, plays an important role in pleasure and reward seeking behaviors, addiction, 
emotion, and perception; the mesocortical pathway, which drives DA from VTA to PFC, is 
critical for attention, learning, memory, cognition and emotional behavior.10,111   
 
1.3.2 Distribution of D2R in the brain 
         D2R is widely distributed in the brain. Various studies including immunostaning and in situ 
hybridization have found high density of D2R in VTA (in rat and mouse tissue samples),112,113 
striatum especially nucleus accumbens (in rat and human striatum tissue samples),112, 114-118 and 
substantia nigra (in rat tissues).112, 117 mRNA of D2R has also been found highly expressed in the 
VTA,118 the striatum,112,114   and the substantia nigra.112 The distribution of D2R in PFC is more 
sparse but has been found in human tissue samples, especially in layers V and VI.114 mRNA of 
D2R has been found in rat PFC pyramidal and GABAergic neurons.119  
 
1.3.3 Signaling of D2R 
         D2R couples to and activates the Gi protein, facilitates the exchange of GDP (within the Gα 
subunit) for GTP, leads to dissociation of the Gα and Gβγ subunits, and induces various 
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downstream signaling pathways. D2R inhibits cyclic AMP (cAMP) levels and various signaling 
proteins such as PKA and CREB via inhibition of adenylyl cyclase. D2R directly activates G 
protein-inwardly rectifying potassium channels (GIRK) through the Gβγ subunits and has also 
been reported to suppress L-type voltage-gated calcium channels and activate muscarinic K+ 
channel and Kv1 channels through the Gβγ subunits.120-23 The activation of GIRK and 
Kv1channels both induce influx of K+, resulting in decreased DA neuronal firing rates or 
inhibited DA release.124 Besides the canonical Gi signaling pathway, D2R also couples to β-
arrestin2 and activates the downstream PP2A-Akt-GSK3 signaling pathway (Figure 1.4 A).125   
 
 
1.3.4 Function of the dopamine system  
         D2R has been found to regulate a broad range of physiological and behavioral processes, 
including reward-motivation, addiction, emotion, perception, attention, working memory, 
learning, blood pressure, gastrointestinal motility, vasodilatation, and locomotion.111 Many 
studies have suggested the function of dopamine receptor heteromers in mental disorders such as 
schizophrenia, addiction, and ADHD (Table 1.1).126  
         The mesolimbic system plays an important role in addiction and reward-motivation. DA 
increase in the striatum induced by various stimulants (e.g. nicotine, alcohol and amphetamine) 
has been shown to be linked to the subjective experience of euphoria by human brain imaging 
studies, using PET.127-129 The greatest DA increases following drug exposures have been found 
to cause the most intense euphoria.127-129 Moreover, D2R increase in the nucleus accumbens has 
been found to increase motivation by decreasing inhibitory transmission to the ventral pallidum 
by in vivo physiological studies.130  
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          The mesocortical system is critical for learning and memory. Cognitive processes of 
learning and memory depend on PFC circuits that are innervated by DA neurons originating in 
the VTA in the mid brain. PFC activity during tasks associated with working memory has been 
found to correlate with phasic DA signals in VTA in fMRI studies.131-133 Blockage of D2R in the 
lateral PFC has been shown to impair learning of new stimuli (response associations and 
cognitive flexibility) in monkeys.134 A direct role of DA in PFC-dependent memory was 
indicated by observations that subjects that were off the DA precursor L-DOPA made more 
errors in a spatial working memory task compared to when they had received L-DOPA.135,136  
           Due to the extensive distribution and function of the dopamine and D2R, dopaminergic 
dysfunction has been implicated in various mental disorders, including schizophrenia, OCD, 
ADHD, addiction, mood disorder, autism spectrum, Tourette’s syndrome, and Parkinson’s 
disease.111  
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1.4 The serotonin system 
 
1.4.1 Serotonin in the brain 
         Serotonin (5-HT) is synthesized from the amino acid L-tryptophan by neurons of the raphe 
nuclei in the mid brain. The raphe nuclei contain the majority of 5-HT neurons that innervate the 
forebrain. 5-HT neurons originating from the raphe nuclei project to prefrontal cortex, cerebral 
cortex, hippocampus as well as VTA and striatum.137,138  
 
1.4.2 Distribution of 2AR 
         2AR is widely distributed in the brain. In the rat brain, 2AR is found to be abundantly 
expressed in the cerebral cortex (especially in layers I, IV, V), and the piriform and entorhinal 
cortex, the claustrum, endopiriform nucleus, and olfactory bulb/anterior olfactory nucleus, 
brainstem, as well as the striatum and the basal ganglia (e.g., nuclear accumbens and caudate 
nucleus).139,140 In the human brain, high density of 2AR is found in laminae III and V of the 
frontal, parietal, temporal, occipital, anterogenual cortices, and entorhinal area by [3H] ketanserin 
studies; 141 mRNA of 2AR is found in all neocortical areas (especially in layer V pyramidal 
neurons and interneurons) by in situ hybridization studies;142 the presence of 2AR in pyramidal 
neurons and interneurons is confirmed by morphological and double immunofluorescence 
studies.143-1145 Besides the cortex, 2AR is also expressed in the striatum, substantia nigra, nucleus 
accumbens, and hippocampus. In both rat and human brain, 2AR is found to be expressed in DA 
neurons in the VTA by immunochemistry studies.146-148 At the subcellular level, 2AR is found 
both pre- and post-synaptically but predominantly at postsynaptic dendritic spines and shafts of 
non-5-HT neurons.149 
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1.4.3 Signaling of 2AR 
         2AR couples to the Gq protein, activates phospholipase C (PLC) via the α subunit of the 
Gq protein, induces the hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP2) into inositol 
trisphosphate (IP3) and di-acyl glycerol (DAG).150 Hydrolysis of PIP2 in general inhibits ion 
channels, including the G protein-inwardly rectifying potassium channels (GIRK). IP3 stimulates 
calcium release from endoplasmic reticulum (ER), whereas DAG stimulates protein kinase C 
(PKC). In the prefrontal cortex, activation of 2AR suppresses membrane Cav1.2 L-type Ca2+ 
currents via Gαq-PLC-IP3-calcineurin signaling pathway.151 Generally, 2AR increases 
intracellular Ca2+ level via Gq-PLC-IP3 signaling pathway, enhances neurotransmission and acts 
as inhibitory or excitatory neuronal modulators. 
         Besides the canonical Gq-PLC-IP3 signaling pathway, 2AR activation also induces the 
Ras-MEK-ERK pathway, RSK2-tyrosine kinase pathway and β-arrestin2-PI3K-Src-Akt pathway 
(Figure 1.4 B).150,153-154   
 
1.4.4 Function of the serotonin system 
         The serotonergic system regulates a broad range of physiological and behavioral processes, 
including learning and memory, cognition, aggression, respiration, endocrine regulation, feeding, 
sleep-wake cycle, pain sensitivity, vascular function, and emesis.155,156  
         The function of 2AR in learning and memory has been shown in both invertebrate and 
vertebrate model systems. Increase in 5-HT levels and 2AR activity has been found to improve 
memory in rodents and in Alzheimer and schizophrenic patients.157,158 In contrast, reduction of 5-
HT and 2AR activity has been found to impair contextual fear memory in mice, object memory 
in rats, and declarative memory in humans.159-161 A large number of studies have shown the 
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learning and memory effects after 2AR pharmacological manipulations across distinct tasks and 
different species.162  
         Polymorphisms and alterations in the human HTR2A gene are associated with altered 
memory processes and disordered cognitive functions. Carriers of the polymorphism-induced 
His452Tyr substitution exhibited impairment in memory recall, poor verbal delayed recall and 
recognition in humans.163-166 Carriers of the homozygous T102C and A-1438G and T-allele 
exhibited significantly impaired short-term verbal memory and spatial working memory.167,168  
          The role of 2AR in mediating hallucination and spatial cognition has been shown in both 
animal models and humans. Serotonergic psychedelics have been found to cause visual or 
auditory hallucinations and paranoid delusions, an effect that can be blocked by administration of 
2AR antagonists.169-171 The 2AR TT genotype (rs6313) has been found to be associated with 
better spatial cognitive performance.172 The 2AR agonist DOI has been found to decrease rat 
performance measured by swim time in both a new maze and a well-learned maze.173  
           Besides schizophrenia associated psychosis, the level of 2AR in the PFC has been found 
to correlate with neuropsychiatric disorders such as anxiety, Alzheimer’s, depression and 
OCD.174-177  
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1.5 Evidence for D2R-2AR heteromerization 
 
         Common distribution of D2R and 2AR occurs in the VTA, striatum and PFC, providing the 
prerequisite for D2R and 2AR heteromeric complex formation. In the last decade, a few reports 
have shown evidence for the co-localization and heteromerization of D2R and 2AR in both native 
and heterologous expression systems.  
         Confocal microscopy image studies and single cell FRET studies revealed the co-
localization of D2R and 2AR in HEK cells co-transfected with YFP-D2R and CFP-2AR.178 
Immunofluorescence staining studies exhibited the co-localization of native D2R and 2AR in rat 
medial prefrontal cortex and substantia nigra.178,179 Co-immunoprecipitation (Co-IP) studies 
suggested interaction between D2R and 2AR, as in HEK293 cells co-transfected with Rluc-D2R 
and GFP-2AR, a GFP antibody pulled down Rluc-D2R and an Rluc antibody pulled down GFP-
2AR.180 BRET studies suggested formation of heteromeric complex between D2R and 2AR, as a 
BRET saturation curve was obtained in HEK293 cells co-transfected with Rluc-D2R and 
increasing amounts of GFP-2AR.181 Proximity ligation assay (PLA) studies revealed a 
heteromeric complex of D2R-2AR in rat striatum (nucleus accumbens and caudate putamen) 
(Figure 1.5).182,183   
         In an animal behavioral study, the effect of haloperidol on reversing MK-801 induced 
locomotion was significantly attenuated in 2AR KO mice, indicating 2AR is necessary for the 
D2R antagonist haloperidol to exert its full antipsychotic effects (Figure 1.6).180  
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1.6 Purpose of this study 
 
 
         The hypothesis and findings that D2R and 2AR may directly interact and form a functional 
heteromeric complex raise a series of questions including:  
         1. Would the signaling properties of D2R and 2AR in the heteromeric complex change 
compared to the homomeric ones?  
         2. How can one manipulate the formation of D2R-2AR heteromeric complex?  
3. How do the D2R and 2AR couple to each other? 
4. Does the effectiveness of antipsychotic drugs depend on the D2R-2AR putative 
heteromer? 
The purpose of this study is to answer these questions. We have pursued four major aims 
for this study: 
1. To profile the Gi and Gq signaling properties of the D2R-2AR putative heteromer 
2. To develop tools to manipulate the formation and function of the D2R-2AR putative 
heteromer in heterologous system and native tissue 
3. To build a structural model of the D2R-2AR putative heteromer recapitulating its 
coupling mechanism. 
4. To investigate the effectiveness of antipsychotic drugs on the function of the D2R-2AR 
putative heteromer.  
We hope that this study provides insights to the function of the D2R-2AR putative 
heteromer in schizophrenia and psychosis, and sheds light towards the long-term goal of 
therapeutic development of more effective antipsychotic drugs.  
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Figure 1.1 Key dopamine pathways in the brain 
The neuroanatomy of dopamine neuronal pathways in the brain can explain the symptoms of 
schizophrenia as well as the therapeutic effects and side effects of antipsychotic drugs.  
(a) Nigrostriatal dopamine pathway  
(b) Mesolimbic dopamine pathway  
(c) Mesocortical dopamine pathway  
(d) Tuberoinfundular dopamine pathway  
(e) Brainstem projections to the thalamus 
Adapted from Stahl (2013) 
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Figure 1.2 Neuronal circuits indicating the interaction between 2AR and glutamate 
receptors in response to psychoactive and antipsychotic agents.  
a. The serotonin and glutamate release induced in the cortex by PCP-like psychoactive drugs 
targeting subcortical NMDA receptors might affect the signaling properties of the cortical 5-
HT2A–mGlu2 receptor complex  
b. Concurrently, these results indicate that both LSD-like and PCP-like psychoactive drugs 
dysregulate the signaling properties of cortical pyramidal neurons and affect cognition and 
perception processes in the brain cortex. 
Adapted from Gonzalez-Maeso et al, Trends in Neurosciences (2009) 
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Figure 1.3 Integrated hypothesis of schizophrenia showing the role of dopamine, serotonin 
and glutamate 
Excess serotonin, upregulated 2AR, or psychedelic hallucinogens all could cause hyperactivation 
of 2AR on glutamatergic neurons in PFC, which leads to glutamate release from PFC to VTA. 
Excessive glutamate in VTA causes hyperactivity of DA mesolimbic pathway and hypoactivity 
of DA mesocortical pathway, resulting in schizophrenic symptoms. 
Adapted from Stahl et al, CNS Spectrums (2018) 
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Figure 1.4 D2R and 2AR signaling pathways 
A. D2R signaling pathways 
B. 2AR signaling pathways 
Adapted from Saunders et al, (2017) 
 
 
               A 
            
 
 
 
 
 
 
 
 
 
                B 
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Table 1.1 Physical and functional evidence for dopamine receptor heteromer 
Dopamine receptor heteromers are involved in many mental disorders such as schizophrenia, 
addition, and ADHD.  
Adapted from Perreault et al, Neuropsychopharmacology (2014) 
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Figure 1.5 Evidence for D2R-2AR heteromerization 
A. BRET saturating curve indicating the formation of D2R-2AR heteromeric complex in HEK 
cells co-transfected with D2R and 2AR.  
Adapted from Borroto-Escuela et al, BBRC (2010) 
B. PLA results indicating the formation of D2R-2AR heteromeric complex in rat striatum 
(caudate putamen) samples.  
Adapted from Borroto-Escuela et al, Methods in Enzymology (2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      B 
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Figure 1.6 2AR is necessary for the inhibition of MK-801-induced locomotor activity by the 
D2R antagonist haloperidol.  
A. The time course of MK-801-induced locomotion is measured in 5 min blocks. Time of 
injections of MK-801 is indicated by arrows. Horizontal activity is measured in wild-type (WT) 
and 5-HT2AR-KO mice.  
B. Corresponding bar graph of the total MK-801-induced locomotion as a summation of 
horizontal activity from t=10 min to t=120 min. Mice were administered haloperidol (1 mg/kg) 
or vehicle followed by MK-801 (0.5 mg/kg; i.p.) (n=6; **p < 0.01; error bars shows SEM). 
Adapted from Albizu et al, Neuropharmacology (2011) 
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Chapter 2. THE INTEGRATED GI AND GQ SIGNALING PROFILE OF D2R-2AR  
 
 
2.1 Background introduction 
2.1.1 Monitoring Gi and Gq activity in an oocyte electrophysiology assay and a mammalian cell 
calcium mobilization assay  
          Fribourg et al. used the oocyte assay to monitor mGluR2-elicited Gi activity and 2AR-
elicited Gq activity.1 In the present study, we have used the same assay to monitor D2R-elicited 
Gi activity and 2AR-elicited Gq activity (Figure 2.1). G protein-gated Inward-Rectifying 
Potassium (K) 4* (GIRK4*) channel was used as reporter. D2R activation opened GIRK4*, 
resulting in current increase, whereas 2AR activation inhibited the opening of GIRK4*, resulting 
in current inhibition.2 The current change upon receptor activation was measured by Two-
Electrode Voltage Clamp (TEVC) and normalized to the basal current induced by 96 mM K+ 
solution to represent Gi and Gq activity. When monitoring Gi activity, RGS2 was used to 
eliminate Gq signaling; when recording Gq activity, PTX was used to inhibit Gi signaling.  
          To avoid the long recording time for Gq current inhibition that made it a challenge to 
construct concentration-response relationships, we adapted the calcium mobilization assay as a 
second method to monitor 2AR-elicited Gq activity. GCaMP, a fusion protein of calmodulin 
(CaM) and permutated GFP was used as calcium indicator.3 2AR activation led to IP3-induced 
Ca2+ release from the endoplasmic reticulum (ER). Ca2+ binds to the CaM moiety and causes a 
structural shift of GFP, resulting in bright fluorescence signals.3 The peak of the fluorescence 
trace was measured and normalized to the basal line to represent the 2AR-elicited Gq activity.  
	 40	
2.1.2 Co-expression of D2R with 2AR potentiates Gi and Gq signaling in response to 1uM DA 
and 5-HT 
         Previous work of Younkin et al. explored the effect of co-expression of D2R with 2AR on 
D2R-elicited Gi activity and 2AR-elicited Gq activity (Figure 2.2). D2R and 2AR were 
expressed in oocytes alone and together. The presence of 2AR significantly increased the Gi 
activity of D2R in response to 1 µM DA, compared to D2R alone (dashed line). Co-addition of 
1 µM DA and 1 µM 5-HT further enhanced the Gi activity of D2R. Similar results were obtained 
for 2AR-elicited Gq activity. Co-expression significantly potentiated the Gq activity of 2AR in 
response to 1 µM 5-HT compared to the 2AR homomer (dashed line). When both ligands were 
applied, the Gq activity of 2AR was further augmented. These results revealed a functional 
cross-talk between D2R and 2AR in response to endogenous ligands.  
 
2.1.3 Ratio of D2R and 2AR expressed in oocytes and HEK293 cells 
         To explore whether the ratio of D2R to 2AR expressed in oocytes has an impact on the 
potentiation of Gi and Gq activity, Youkin et al. injected cRNA of D2R and 2AR with different 
ratios in oocytes and tested the DA-induced Gi activity and 5-HTinduced Gq activity (Figure 2.3 
A and B). The results show the greatest Gi and Gq potentiation was obtained when the cRNA of 
D2R to 2AR injected was at a ratio of 1:2.  
        To determine the ratio of D2R and 2AR that gives the greatest potentiation of Gq activity in 
HEK293E cells, cDNA of D2R and 2AR was co-transfected with different ratios in HEK293E 
cells and the Gq activity was measured (Figure 2.3 C and D). The results showed the greatest 
potentiation of Gq activity in response to 0.1 µM 5-HT or 10 µM DA is when cDNA of D2R and 
2AR was co-transfected at a ratio of 1:1. 
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Based on these results, D2R and 2AR were co-injected at a ratio of 1:2 in oocytes, and co-
transfected at a ratio of 1:1 in HEK293E cells in all subsequent experiments, to achieve maximal 
functional cross-talk. 
 
2.1.4 Aims 
        The work of Youkin et al. showed functional cross-talk between D2R and 2AR in response 
to 1 µM DA and 5-HT. However, it was not determined whether the positive modulation of Gi 
and Gq signaling would be observed only in response to 1 µM DA and 5-HT or whether the 
potentiation was dependent on the concentration of DA and 5-HT. In order to obtain the Gi and 
Gq signaling properties of D2R-2AR putative heteromer, we decided to perform full dose-
response curves for D2R-2AR co-expression and compare them to those from D2R and 2AR 
expressed alone. We expected that dose-response relationships would characterize the Gi and Gq 
activities of the D2R-2AR putative heteromer in response to ligands at a broad range of 
concentrations, and provide pharmacological information of its signaling properties, such as 
potency and efficacy and show where the 1 µM concentration fell in the dose-response curves.  
 
2.2 Results and discussion 
 
2.2.1 Co-expression of D2R with 2AR potentiates DA induced Gi signaling 
         To obtain the Gi signaling profile of D2R homomer and D2R-2AR putative heteromer, 
seven doses of DA were applied to oocytes expressing either D2R alone or D2R and 2AR 
together (Figure 2.4). In the full range of the dose-response curves, Gi activity obtained through 
D2R-2AR co-expression was markedly enhanced compared to D2R alone. The Emax of the two 
	 42	
curves indicated that the presence of 2AR doubled the efficacy of DA. The EC50 values of the 
two curves were similar, indicating that the presence of 2AR did not exert a major effect on the 
potency of DA. In both curves, DA saturated at 1 µM.  
 
2.2.2 Co-expression of D2R with 2AR enables 5-HT induced Gi signaling 
         When repeating Youkin’s experiments, I observed that Gi signaling could be obtained 
when 1 µM 5-HT was applied to oocytes co-expressing D2R and 2AR. To explore whether 5-HT 
induced D2R-elicited Gi signaling in the presence of 2AR, six doses of 5-HT were applied to 
oocytes expressing D2R and 2AR alone or together (Figure 2.5). The results show that in the 
absence of DA, 5-HT generated Gi signaling in a dose-dependent manner in oocytes co-
expressing D2R and 2AR. Because RGS2 was co-expressed to eliminate Gq signaling when 
monitoring Gi activity, the activation of D2R upon addition of 5-HT could not be due to the 
2AR-Gq downstream signaling pathway. Thus, we interpret the 5-HT-induced Gi signaling as 5-
HT stimulating 2AR, then somehow the stimulated 2AR further activating D2R and inducing Gi 
signaling. Interestingly, here 5-HT saturates at 10 µM, the same as the saturating concentration 
of 5-HT acting on the 2AR homomer. In control experiments, 5-HT does not generate Gi-
signaling on the 2AR homomer because the 2AR homomer does not couple to the Gi protein; 
only a small amount of Gi activity was observed when micromolar doses of 5-HT were applied 
to the D2R homomer.  
 
2.2.3 Integrated Gi signaling of D2R-2AR co-expression in response to DA and 5-HT   
         Comparison of Emax in Figure 2.6 A and B shows that co-expression of D2R and 2AR 
enhanced the efficacy of DA or 5-HT-induced Gi activity compared with the efficacy of DA on 
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D2R homomer. Inclusion of 0.5 µM 5-HT (close to the EC50 of 5-HT) with DA further 
potentiated the Gi signaling through D2R-2AR co-expression and enhanced the potency of DA. 
These results suggest that 2AR positively modulates the Gi signaling of D2R.  
          
2.2.4 Co-expression of D2R with 2AR potentiates 5-HT-induced Gq signaling 
         To obtain the Gq signaling profile of 2AR homomer and D2R-2AR putative heteromer, 
eight doses of 5-HT were applied to HEK293E cells expressing 2AR alone and D2R with 2AR 
respectively (Figure 2.7). In the full range of the dose-response curves, the presence of D2R 
significantly increased the 2AR-elicited Gq signaling compared with 2AR homomeric Gq 
signaling. The Emax values of the two curves indicates the presence of 2AR significantly 
enhances the efficacy of DA. EC50 of the two curves are comparable, indicating the presence of 
2AR does not change the potency of 5-HT. In both curves, 5-HT saturates at 0.1 µM.  
 
2.2.5 Co-expression of D2R with 2AR enables DA-induced Gq signaling 
          To explore whether DA induces 2AR-elicited Gq signaling in the presence of D2R, eight 
doses of DA were applied to HEK293E cells expressing D2R and 2AR alone or together (Figure 
2.8). The results showed that in the absence of 5-HT, DA generated Gq signaling in a dose-
dependent manner in cells co-expressing D2R and 2AR. In control experiments, the DA-induced 
Gq-signaling on the D2R homomer was negligible due to the fact D2R homomer does not couple 
to Gq proteins. A small amount of Gq activity was detected when DA above the micromolar 
range was applied to the 2AR homomer. This observation is consistent with previous findings of 
Woodward et al. and Bhattacharyya et al. that DA at micromolar concentrations acts as a partial 
efficacy agonist of 2AR in Xenopus oocytes and HEK293 cells.4,5 Notably, the DA induced Gq 
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signaling of 2AR homomer is markedly smaller than that of D2R-2AR co-expression. Thus, we 
interpret the DA-induced Gq signaling as stimulated D2R by DA activating 2AR and eliciting Gq 
signaling. 
 
2.2.6 Integrated Gq signaling of D2R-2AR in response to DA and 5-HT   
         Comparison of Emax values in Figure 2.9 A and B shows that co-expression of D2R and 
2AR enhanced the efficacy of 5-HT or DA-induced Gq activity compared with the efficacy of 5-
HT acting on the 2AR homomer. Co-addition of 0.75 µM DA (the EC50 of DA) with 5-HT 
further potentiated the Gq signaling through D2R-2AR co-expression and enhanced the potency 
of 5-HT. These results suggest that D2R positively modulates the Gq signaling of 2AR. 
 
2.2.7 Co-expression of D2R with 2AR potentiates Gi and Gq signaling 
         The dose-response results in Figures 2.4-2.9 reveal both Gi and Gq signaling are 
potentiated upon D2R-2AR co-expression (Figure 2.10). The presence of 2AR increases the Gi 
signaling of D2R in response to either DA (cis-signaling) or 5-HT (trans-signaling); co-addition 
of both ligands further increases Gi signaling (combination of cis and trans-signaling). 
Symmetrically, the presence of D2R increases the Gq signaling of 2AR in response to either 5-
HT (cis-signaling) or DA (trans-signaling); when both ligands are applied, the Gq signaling is 
further augmented (combination of cis and trans-signaling).  
 
2.2.8 D2R synthetic ligands cross-talk to 2AR  
         Quinpirole (QP), a selective D2R/D3R agonist and psychoactive drug has been found to 
induce D2R super-sensitivity, and therefore it has been used in animal models of schizophrenia.  
	 45	
6-8 Haloperidol (HLP), a typical antipsychotic drug with high affinity to D2R and strikingly low 
affinity to 2AR has been widely used in the treatment of schizophrenia.9-11 In this study, we 
applied multiple doses of QP or HLP to HEK cells co-expressing D2R and 2AR, to assess 
whether D2R synthetic ligands cross-talk to 2AR (Figure 2.11). As the dose-response curve 
shows, quinpirole generates robust Gq signaling in the absence of 5-HT whereas haloperidol 
decreases 5-HT induced Gq signaling. Although control experiments testing Gq signaling in 
response to QP on 2AR homomer has not been performed, it has not been reported in the 
literature that QP can act as partial or full agonist of 2AR. Results in Figure 5.3 suggest that the 
presence of D2R significantly increases the potency of HLP antagonizing the 5-HT-induced 
2AR-elicited Gq signaling. Thus, we conclude that QP and HLP cross-talk to act on 2AR.  
 
2.2.9 D2R synthetic ligands cross-talk to modulate 2AR agonist-induced Gq signaling 
         To explore whether QP modulates 2AR agonist-induced Gq signaling, 0.1 µM QP was 
applied with 5-HT or DOI to cells co-expressing D2R and 2AR (Figure 2.12). The upward- and 
left-shift of the dose-response curves shows that QP potentiated Gi signaling and enhanced the 
potency of 5-HT and DOI acting on the D2R-2AR co-expression, indicating that QP cross-talks 
to positively modulate 2AR agonist-induced Gq signaling.  
         To assess HLP’s effect on modulating 2AR agonist-induced Gq signaling, 15 µM and 10 
µM HLP was applied with 5-HT and DOI respectively to cells co-expressing D2R and 2AR 
(Figure 2.12). The right shift of the dose-response curves shows that HLP decreases the potency 
of 5-HT and DOI acting on D2R-2AR co-expression, indicating that HLP cross-talks to 
negatively modulate 2AR agonist-induced Gq signaling.  
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2.3 Summary 
            In this study, we obtained full-dose response curves of DA and 5-HT on oocytes and 
HEK cells co-expressing D2R and 2AR. Co-expression of D2R and 2AR potentiates Gi and Gq 
signaling compared to D2R homomer and 2AR homomer and reveals the signaling properties of 
D2R-2AR putative heteromer.  
           We summarize our results and conclusions as follows: 
1. Co-expression of D2R and 2AR potentiates Gi cis-signaling in response to DA 
2. Co-expression of D2R and 2AR enables Gi trans-signaling in response to 5-HT 
3. Co-expression of D2R and 2AR potentiates Gq cis-signaling in response to 5-HT 
4. Co-expression of D2R and 2AR enables Gq trans-signaling in response to DA 
5. Co-addition of DA and 5-HT further potentiates Gi and Gq signaling.  
6. QP cross-talks to activate 2AR and positively modulate 2AR agonist-induced Gq 
signaling 
7. HLP cross-talks to antagonize 2AR and negatively modulate 2AR agonist-induced Gq 
signaling. 
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Figure 2.1 Monitoring Gi and Gq Signaling with Inward-Rectifying Potassium Channels in 
Xenopus Oocytes and Calcium mobilization assay with Calcium indicator GCaMP  
A. Stimulation of a Gi-coupled receptor, such as D2R, activates Gβγ subunits to stimulate GIRK 
channel currents. PTX is shown to inhibit Gi signaling. 
B. Stimulation of a Gq-coupled receptor, such as 2AR, activates PLC to hydrolyze PIP2 via Ga 
subunit, resulting in inhibition of the IRK3 (or GIRK) channel currents. RGS2 is shown to 
inhibit Gq signaling. 
Adapted from Hatcher-Solis et al., Current Pharmaceutical Biotechnology (2014) 
C. Stimulation of a Gq-coupled receptor, such as 2AR, activates PLC to hydrolyze PIP2 to IP3, 
resulting in IP3 induced Calcium release from endoplasmic reticulum (ER). Calcium binds to 
calmodulin (CaM) and activate the GPF in GCaMP, resulting in the generation of fluorescence 
signals. 
Adapted from Lindenburg et al., Sensor (2014) 
D. Representative barium-sensitive traces of GIRK4* currents obtained in oocytes expressing 
D2R in response to 96 mM potassium solution (basal), 1 µM DA, and 3mM barium solution. 
Barium inhibits GIRK4* currents and allows for subtraction of GIRK4*-independent currents. 
E. Representative barium-sensitive traces of GIRK4* currents obtained in oocytes expressing 
2AR in response to 96 mM potassium solution (basal), 1 µM serotonin (5-HT), and 3 mM 
barium solution.   
F. Representative fluorescence traces of GCaMP obtained in HEK293E cells expressing 2AR in 
response to 0.1 µM 5-HT. The time point of 5-HT application is indicated by the arrow.  
 
 
 
A                                                 B                                                      C 
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Figure 2.2 Co-expression of D2R with 2AR potentiates Gi and Gq signaling in response to 
1 µM DA and 5-HT 
Bar graph summary of Gi activity (yellow) and Gq activity (red) measured in oocytes. Dashed 
line represents the Gi and Gq activity of D2R homomer and 2AR homomer. The presence of 
2AR increases the Gi activity of D2R in response to 1 µM DA, co-addition of 1 µM DA and 
1µM 5-HT further enhances Gi activity. The presence of D2R increases the Gq activity of 2AR in 
response to 1uM 5-HT, co-addition of 1 µM DA and 1 µM 5-HT further enhances Gq activity.  
Adapted from Younkin et al. 
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Figure 2.3 The ratio of D2R and 2AR expressed in oocytes and HEK293 cells 
A. and B. The largest Gi and Gq potentiation is obtained when oocytes co-expressing D2R and 
2AR with raio of 1:2. Gi activity (GIRK4* current activation) was measured relative to the basal 
currents and was normalized relative to the activation of D2R by 1 µM DA (100% or 1) (dashed 
line). Gq activity (GIRK4* current inhibition) was measured relative to the basal currents and 
was normalized relative to the activation of 2AR by 1 µM 5-HT (100% or 1) (dashed line). 
(Mean ± SEM. N=7-8/condition. *p<0.05, **p<0.01) 
Adapted from Younkin et al. 
C. and D. Bar graph summary showing the greatest Gq activity in response to 0.1 µM 5-HT or 
10 µM DA is obtained when D2R and 2AR is co-expressed with ratio of 1:1 in HEK293 cells.  
Gq activity was measured relative to the basal florescence and was normalized relative to the 
activation of 2AR by 0.1 µM 5-HT (100). (Mean± SEM. N=8/condition) 
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Figure 2.4 Co-expression of D2R with 2AR potentiates DA induced Gi signaling 
A. Representative barium-sensitive traces of GIRK4* currents obtained in response to sequential 
addition of 1 nM, 10 nM, 32 nM, 100 nM, 320 M, 1 µM and 10 µM DA in oocytes expressing 
D2R alone (left panel), D2R with 2AR (right panel). (orange: outward current; blue: inward 
current) 
B. Dose-response curves showing the efficacy of DA on oocytes co-expressing D2R and 2AR 
(yellow, Emax=2.15) is increased by ~100% compared with oocytes expressing D2R alone (black, 
Emax=1.09). Gi activity (GIRK4* current activation) was measured relative to the basal currents 
and was normalized relative to the maximal activation of D2R by DA (100% or 1) (Mean ± 
SEM; N=6-7/condition). RGS2 was co-injected to inhibit Gq signaling. 
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Figure 2.5 Co-expression of D2R with 2AR enables 5-HT induced Gi signaling 
A. Representative barium-sensitive traces of GIRK4* currents obtained in response to sequential 
addition of 1 nM, 10 nM, 100 nM, 1 µM, 10 µM, 100 µM 5-HT and 10 µM DA in oocytes co-
expressing D2R and 2AR. (orange: outward current; blue: inward current) 
B. Dose-response curves showing 5-HT induces robust Gi trans-signaling in the absence of DA 
on oocytes co-expressing D2R and 2AR (yellow, Emax=1.47), but not on oocytes expressing D2R 
alone (gray solid, Emax=0.26) or 2AR alone (gray dash, Emax=0.07). Gi activity was measured and 
normalized as Figure 2.4B (Mean± SEM; N=4-6/condition). RGS2 was co-injected to inhibit Gq 
signaling. 
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Figure 2.6 Integrated Gi signaling of D2R-2AR in response to DA and 5-HT   
A. Dose-response curves showing the addition of 0.5 µM 5-HT with DA further increases the 
efficacy of DA on oocytes co-expressing D2R and 2AR (orange, Emax=2.79). Gi activity was 
measured and normalized as Figure 2.3B (Mean± SEM; N=4-7/condition). RGS2 was co-
injected to inhibit Gq signaling. 
B. Same as Figure 2.5B 
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Figure 2.7 Co-expression of D2R with 2AR potentiates 5-HT induced Gq signaling 
Dose-response curves showing the efficacy of 5-HT on HEK293 cells co-expressing D2R and 
2AR (red, Emax=126.7) is increased compared with cells expressing 2AR alone (black, 
Emax=101.8). Gq activity was measured relative to the basal florescence and was normalized 
relative to the Emax of 2AR by 5-HT (100). (N=6/condition) 
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Figure 2.8 Co-expression of D2R with 2AR enables DA induced Gq signaling 
Dose-response curves showing DA generates robust Gq trans-signaling in the absence of  
5-HT on HEK293 cells co-expressing D2R and 2AR (red, Emax=110.6), but not on cells 
expressing 2AR alone (gray solid, Emax=25.4) or D2R alone (gray dash, Emax=12.7). Gq activity 
was measured and normalized as Figure 2.7. (N=6/condition) 
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Figure 2.9 Integrated Gq signaling of D2R-2AR in response to DA and 5-HT   
A. Dose-response curves showing the addition of 0.75 µM DA increases the efficacy and the 
potency of 5-HT on HEK293 cells co-expressing D2R and 2AR (orange, Emax=158.1). Gq 
activity was measured and normalized as Figure 2.7. (Mean± SEM; N=6/condition) 
B. Same as Figure 2.7 
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Figure 2.10 Co-expression of D2R with 2AR potentiates Gi and Gq signaling 
 
A. Schematic Gi signaling of D2R and D2R+2AR showing the presence of 2AR increases the Gi 
signaling of D2R in response to either DA (cis-signaling) or 5-HT (trans-signaling); when both 
ligands are applied, the Gi signaling is further increased (combination of cis and trans-signaling).  
B. Schematic Gq signaling of 2AR and D2R+2AR showing the presence of D2R increases the Gq 
signaling of 2AR in response to either 5-HT (cis-signaling) or DA(trans-signaling); co-addition 
of both ligands further augmented Gq signaling (combination of cis and trans-signaling).  
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Figure 2.11 D2R synthetic ligands cross-talk to 2AR 
A. Dose-response curves showing quinpirol cross-talks to activate 2AR.  
B. Dose-response curves showing haloperidol cross-talks to antagonize 5-HT at 2AR.  
Gq activity was measured relative to the basal florescence. (Mean± SEM; N=6/condition) 
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Figure 2.12 D2R ligands cross-talk to allosterically modulate 2AR agonist induced Gq 
signaling 
A. Dose-response curves showing the addition of 0.1 µM QP increases both the efficacy and 
potency of 5-HT on HEK293E cells co-expressing D2R and 2AR (orange, Emax=121.8), while the 
addition of 15 µM HLP decreases the potency of 5-HT (purple, Emax=94.4).  
B. Dose-response curves showing the addition of 0.1 µM QP increases both the efficacy and 
potency of DOI on HEK293E cells co-expressing D2R and 2AR (orange, Emax=115.1), while the 
addition of 10 µM HLP decreases the potency of 5-HT (purple, Emax=100).  
Gq activity was measured relative to the basal florescence and was normalized relative to the 
maximal activation of D2R-2AR by 5-HT or DOI in the absence of D2R ligand (100). (Mean± 
SEM; N=6/condition) 
                                      A 
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Chapter 3. DEVELOPING TOOLS TO DISRUPT THE FORMATION AND FUNCTION OF 
D2R-2AR IN HETEROLOGOUS SYSTEM AND NATIVE TISSUE 
 
 
3.1 Background introduction 
 
3.1.1 Use of cell-penetrating peptides as tools to disrupt GPCR heteromers 
          To verify the signaling change upon D2R and 2AR co-expression is due to formation of 
D2R-2AR heteromeric complex, we need tools that disrupt D2R-2AR heteromer formation and 
attenuate D2R-2AR heteromer-induced signaling, thereby confirming the integrated signaling we 
monitored through D2R and 2AR co-expression displays the signaling properties of D2R-2AR 
heteromer. Since 1988 Frankel et al. discovered that the Human Immunodeficiency Virus (HIV) 
Trans-activator of transcription (TAT) protein possessed the ability to permeate cell membranes 
,1 the cell-penetrating peptide (CPP) has been used as a tool in therapeutic delivery2-5 and GPCR 
heteromer studies.6 In the use of CPP to disrupt GPCR heteromer, CPP such as TAT peptide is 
fused to synthetic peptides mimicking and targeting the heteromer interfaces to facilitate their 
translocation to cell membrane.6 Synthetic peptides delivered on cell membrane disrupt 
heteromer formation through competition binding. Here, we use three examples to represent the 
use of CPP as tools to disrupt GPCR heteromers in vitro, ex vivo and in vivo, respectively.  
         Bonaventura et al. applied TAT- tagged synthetic peptides mimicking the TM5/7 of D2R or 
2AR in HEK293 cells co-expressing D2R and A2AR to assess their ability to disrupt the D2R-
A2AR heteromer (Figure 3.1).7 Their fluorescence complementation assay results showed that 
the D2R TM5 peptide and A2AR TM5 peptide significantly decreased the fluorescence between 
D2R and A2AR, suggesting D2R TM5 and A2AR TM5 peptides possess the ability to disrupt D2R-
A2AR heteromer.  
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          Navarro et al. treated rat striatum neurons with TAT-tagged synthetic peptide mimicking 
TM4, 5, 6, 7 of D2R and TM4, 5, 6, 7 of A2AR, and detected D2R-A2AR heteromers by Ploximity 
Ligation Assay (PLA) (Figure 3.2).8 Their results showed D2R TM4 and TM5 peptides and 
A2AR TM4 and TM5 peptides disrupted endogenous D2R-A2AR heteromer in striatum samples, 
indicating D2R and A2AR heteromerize through a symmetric TM4,5-TM4,5 interface. 
         Liu et al. injected TAT-tagged synthetic peptide into the spinal cord of mice to assess the 
function of the mu opioid receptor and gastrin releasing peptide receptor MOR1D-GRPR (Figure 
3.3).9 This synthetic peptide contained a RNEEPSS motif in the MOR1D C terminus which was 
found necessary for MOR1D-GRPR heteromerizaiton. Their animal behavioral results showed 
that MOR1DCT peptide blocked morphine-induced scratching without affecting GRP-induced 
scratching or morphine-induced analgesia, suggesting opioid- induced itch was independent of 
opioid analgesia through the function of MOR1D-GRPR heteromer.  
 
3.1.2 The role of the pre-frontal cortex (PFC) in schizophrenia 
         The PFC mediates cognitive and executive functions required for goal-directed behavior, 
such as working memory, decision-making and selective attention.10-13 Dysfunction of the PFC is 
a key component of the pathophysiology underlying the negative and cognitive symptoms of 
schizophrenia.14,15 Neuroimaging studies in schizophrenic patients and drug addicts have shown 
“task-related hypofrontality” --- decreased basal and working memory task-induced regional 
cerebral blood flow specific to PFC.16-19 Changes in the intrinsic properties of layer V pyramidal 
neurons have been found in cocaine treated rats.20,21 Alteration of neuronal excitability and short-
term synaptic plasticity in PFC are found in mouse models of schizophrenia.22,23 Deficits in LTD 
are found both in patients and MK-801models of schizophrenia.24,25 Taken together, abnormal 
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neuronal excitability and impaired synaptic plasticity in PFC are associated with the 
pathophysiology of schizophrenia. 
          Both 2AR and D2R have been found in the rodent PFC and are abundantly expressed in 
pyramidal neurons and interneurons, especially in layer V.26-28 D2R activation results in 
decreased neuronal excitability and inhibitory postsynaptic potentials.29 VTA DA neurons are 
found to be under excitatory control of 2AR in medial PFC.30, 31  
 
3.13 The role of the ventral tegmental area (VTA) in schizophrenia 
          The VTA is closely related to the pathogenesis of schizophrenia.32 DA neurons in the VTA 
project to the striatum nucleus accumbens and the prefrontal cortex.32,33 Dysfunction of VTA 
underlies hyperdopaminergic states in the striatum and hypodopaminergic states in the PFC, 
characteristic of schizophrenia.32,33 MRI studies showed significantly decreased signal intensity 
of the VTA in patients with schizophrenia.34 Morphology studies showed hypoplasticity and 
reduced number and small size of VTA DA neurons in drug-naïve patients with schizophrenia.35-
37. In vivo electrophysiology studies showed antipsychotic drug effectiveness correlated with 
normalization of VTA function.38,39 
           D2R and 2AR are both expressed in VTA and control VTA neuronal activity. 2AR is 
natively resident within VTA DA neurons.40-42 Interaction between D2R and 2AR in the VTA 
controls D2 receptor trafficking, determining the sensitivity of DA neurons to autoreceptor 
regulation.43 In animal model studies, cocaine-evoked locomotor activity has been found 
increased by viral-mediated overexpression of 2AR in VTA and blocked by intra-VTA 
microinjection of a selective 2AR antagonist, suggesting a role of VTA 2AR in modulating 
psychotic behavior.44,45  
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3.14 Aims 
        In this study, we adapt the CPP strategy to develop tools to manipulate the formation and 
function of D2R-2AR heteromer, as this strategy has been successfully used to disrupt multiple 
GPCR heteromers in vitro, ex vivo and in vivo. We first aim to assess the ability of CPPs in 
disrupting the heteromeric formation and signaling of D2R-2AR in oocytes and HEK cells (in 
vitro), then apply them in brain slice recordings to determine whether the D2R-2AR heteromer 
exists and has a function in PFC and VTA neurons (ex vivo). Finally, we will apply these 
peptides in animal behavioral studies to investigate the function of the the D2R-2AR heteromer 
on mediating psychotic behavior (hyperlocomotor activity) and on the action of antipsychotic 
drugs (in vivo).  
 
3.2 Results and discussion 
 
3.2.1 CPPs mimicking TM5/6 of D2R and 2AR disrupt the formation of D2R-2AR heteromer  
         To assess the ability of peptides disrupting D2R-2AR heteromer, our collaborating Ferré lab 
at the NIH synthesized eight peptides that mimic TM4-7 of D2R and 2AR respectively. The TAT 
peptide was fused to the N-terminus of TM5 and TM7 peptides, and the C-terminus of TM4 and 
TM6 peptides to facilitate their translocation and correct orientation in the cell membrane. 
Robust fluorescence signals induced by complementation of YFP were detected in HEK293 cells 
co-expressing D2R-nYFP and 2AR-cYFP but not in cells co-expressing negative control 
combinations, suggesting the formation of a D2R-2AR heteromeric complex in HEK cells 
(Figure 3.4). Cells co-expressing D2R and 2AR were incubated 4 h with 4 µM of each peptide. 
D2R TM5 and TM6 peptides as well as 2AR TM5 and TM6 peptides eliminated the fluorescence 
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signals between D2R and 2AR, suggesting that these peptides possessed the ability to disrupt the 
formation of D2R-2AR heteromeric complex.  
 
3.2.2 D2R TM5 peptide disrupts D2R-2AR heteromeric signaling 
         We used the D2R TM5 peptide from the Ferré lab to assess its ability to disrupt D2R-2AR 
heteromeric signaling. Oocytes expressing D2R alone or D2R with 2AR were incubated 4 h with 
10 uM D2R TM5 peptide (Figure 3.5). D2R TM5 peptide had no impact on D2R homomeric Gi 
signaling, but abolished the Gi cis-signaling enhancement in response to DA in oocytes co-
expressing D2R and 2AR that is observed without peptide treatment. More strikingly, the Gi 
signaling augmentation in response to co-addition of DA and 5-HT was also taken away after 
treatment with the TM5 peptide. These results suggest the TM5 peptide disrupts the heteromeric 
Gi signaling of D2R -2AR heteromer (the negative control experiment with the D2R TM7 peptide 
is underway). In the calcium mobilization assay, D2R TM5 but not TM7 peptide significantly 
reduced the DA-induced Gq trans-signaling in HEK293 cells co-expressing D2R and 2AR 
without inhibiting the Gq signaling of 2AR homomer, indicating the TM5 peptide disrupts the 
heteromeric Gq signaling of the D2R -2AR heteromer (Figure 3.6). Taken together, we conclude 
from these results that D2R TM5 peptide disrupts the heteromeric signaling of D2R -2AR 
heteromer.  
 
3.2.3 D2R TM5 peptide reverses the enhancement of field Excitatory postsynaptic potential 
(fEPSP) in PFC neurons 
          The collaborating Sidiropoulou lab at the University of Crete, Greece applied the D2R 
TM5 and TM7 peptides in brain slice recordings to assess whether disruption of D2R and 2AR 
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heteromers in PFC affected PFC synaptic activity (Figure 3.7). In their previous study, the field 
excitatory post-synaptic potential (fEPSP) of PFC neurons in brain slices was found to be 
significantly enhanced in response to co-addition of DA and 5-HT but not DA or 5-HT alone. 
This effect was hypothesized to be a function of D2R-2AR heteromer in PFC neurons. 
Application of D2R TM5 or TM7 peptide in field recordings showed the enhancement of fEPSP 
upon 5-HT and DA stimulation was reversed by the TM5 but not TM7 peptide. Considering that 
the D2R TM5 peptide disrupts the formation and function of D2R-2AR heteromer, these results 
suggest D2R and 2AR form heteromeric complex in the PFC and modulate the postsynaptic 
activity of PFC neurons.  
 
3.2.4 D2R TM5 peptide disrupts DA desensitization in VTA neurons 
         It is known that DA inhibits excitation of VTA dopaminergic neurons and reduces their 
firing rate.43 Prolonged exposure to DA reverses the DA-induced neuronal inhibition, a 
phenomenon called DA desensitization or Dopamine Inhibition Reversal (DIR) (Figure 3.8 A).46  
Brodie et al. found this desensitization is dependent on Gq, phospholipase C, protein kinase C, 
G-protein receptor kinase and dynamin.47-52 Given that Gq signaling pathway is required for DA 
desensitization, it is hypothesized that D2R-2AR heteromer is involved in and is necessary for 
DA desensitization in VTA neurons. To test this hypothesis, our collaborating Brodie lab at the 
University of Illinois in Chicago applied the D2R TM5 peptide in the DA desensitization assay. 
The results that DA desensitization is removed after treatment of the TM5 peptide supports this 
hypothesis and suggests a role of D2R-2AR heteromer in modulating the activity of VTA 
neurons (the negative control experiment with the D2R TM7 peptide is underway).  
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3.2.5 A mini gene method to disrupt the D2R-2AR heteromer 
         Besides the disruptive peptide method, I sought to adopt a parallel unique strategy that 
could systematically and readily identify different regions of the interacting receptors critical for 
heteromerization (including non-TM regions). I used the bifunctional vector pXoom (expresses 
both in Xenopus oocytes and mammalian cells) to generate a construct that includes the region of 
interest (e.g., the D2R TM5) preceded by the first 45 aa of the rat somatostatin receptor 3 (sstr3), 
which contains a plasma membrane (PM) localization signal and has been used to localize 
proteins to the PM that otherwise show poor cell surface localization.53 Digestion with specific 
restriction enzymes allows replacement of TM5 with any other region of D2R that could be 
critical in its interactions with 2AR. The first preliminary tests with the TM5 mini gene 
expression in Xenopus oocytes (Figure 3.9) have been promising enough, showing that the TM5 
mini gene abolished the heteromeric Gi signaling. Along with optimizing the experimental 
conditions (e.g. level of mini gene expression) I have started to construct additional D2R TM 
mini genes (positive control: TM6, negative controls: TM4 and TM7) to disrupt D2R-2AR 
heteromerization. Once this assay is fully established, it will enable us not only to test for the 
involvement of all TMs but also any part of the protein that may be involved in enabling 
heteromerization. Moreover, identification of the key protein regions involved in 
heteromerization will provide important constraints for structural models of D2R-2AR 
heteromers. The mini gene approach will be an efficient and cost effective method to identify 
interacting surfaces between GPCRs. Any region of a receptor could be tested for effects on 
heteromer formation before ordering the appropriate peptides for ex vivo and in vivo studies. 
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3.3 Summary 
         In this series of experiments, we successfully developed TAT-tagged synthetic peptide as 
tools to disrupt D2R-2AR putative heteromer in heterologous systems and in ex vivo brain slices. 
In vivo animal behavior experiments using the disruptive peptides are ongoing in the 
collaborating Gonzalez-Maeso lab at Virginia Commonwelath University.  
        We summarize our results and conclusions as follows: 
        1. D2R and 2AR form a heteromeric complex in heterologous systems. 
        2. TAT-tagged synthetic peptides mimicking TM5 and TM6 of D2R or 2AR disrupt D2R-
2AR heteromeric complex in heterologous systems. 
        3. TM5 and TM6 of D2R and 2AR are involved in D2R-2AR heteromeric interface. 
        4. D2R TM5 peptide disrupts the heteromeric signaling of D2R-2AR in heterologous 
systems. 
        5. D2R and 2AR form a heteromeric complex in PFC and VTA neurons. 
        6. The D2R TM5 peptide disrupts the formation and function of D2R-2AR heteromer in PFC 
and VTA neurons.  
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Figure 3.1 Cell-penetrating peptides mimicking D2R TM5 and A2AR TM5 but not D2R 
TM7 and A2AR TM7 disrupt A2AR R-D2R heteromerization in HEK293 cells 
A. Fluorescence (AU) induced by complementation of YFP Venus in HEK-293 cells co-
expressing A2AR-nYFP and A2AR-cYFP, D2R-nYFP and D2R-cYFP, or A2AR-nYFP and D2R-
cYFP treated or not treated with the indicated HIV TAT peptides (4 µM) for 4 h.  
B. BRET (mBU) induced by bimolecular luminescence and fluorescence complementation in 
cells expressing A2AR-nRluc, D2R- cRluc, A2AR-nYFP and D2R-cYFP, and negative controls.  
Adapted from Bonaventura et al., PNAS (2015) 
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Figure 3.2 A2AR and D2R TM4-TAT and TAT-TM5 peptides disrupt A2AR-D2R 
heteromerization and function in striatal neurons 
a. and c. A2AR-D2R heteromer detected by proximity ligation assay (PLA) in rat striatal neurons. 
A2AR-D2R heteromers appeared as red dots in confocal microscopy images. Samples were 
treated with medium (a) or indicated TM peptides of A2AR or D2R (4 µM) for 4 h (c).  
b. Quantification from a and c: values are expressed as the ratio between the number of red spots 
and the number of cells showing spots (r); % values represent the percentage of cells showing 
one or more red spots as compared to control.  
d. and e. cAMP production determined in rat striatal neurons incubated 4 h with 4 µM of 
indicated TM peptides of A2AR (d) or D2R (e) and exposed to indicated ligands. Values are 
expressed as percentage of cAMP accumulation in non-treated cells (basal). 
Adapted from Navarro et al., Nature Communication (2018) 
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Figure 3.3 TAT-MOR1DCT peptide disrupts MOR1D-GRPR heteromerization and 
function in mice 
A. Tat-MOR1DCT peptide contains TAT domain and the RNEEPSS motif in MOR1D C 
terminus. Control peptide contains Tat domain and scrambled sequence of MOR1DCT.  
B. and C. Tat-MOR1DCT blocked morphine-induced scratching without affecting GRP-induced 
scratching (B) or morphine-induced analgesia (C). *p < 0.05. 
D. Co-IP by anti-MOR1D. 
E. Quantified O.D. ratio of GRPR and MOR1D from (D). 
Adapted from Liu et al., Cell (2011) 
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Figure 3.4 Cell-penetrating peptides mimicking D2R or 2AR TM5 and TM6 disrupt D2R-
2AR heteromerization in HEK293 cells 
(In collaboration with Ferre lab at NIH) 
Fluorescence induced by complementation of YFP Venus in HEK-293 cells co-expressing D2R-
nYFP and 2AR-cYFP, not treated or treated 4 h with indicated HIV TAT peptide (4 µM). (**** 
p<0.0001, ANOVA with Dunnet’s multiple comparisons; n=6-8) 
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Figure 3.5 D2R TAT-TM5 disrupts the heteromeric Gi signaling of D2R-2AR in oocytes 
Bar graph summary of Gi activity measured in oocytes expressing D2R alone, D2R with 2AR, 
not incubated or incubated 4 h with 10 µM D2R TAT-TM5 peptide, in response to 1 µM DA or 
1 µM DA with 1 µM 5-HT. Incubation with D2R TAT-TM5 peptide abolishes the Gi cis-
signaling enhancement and the Gi trans-signaling, without affecting D2R homomeric Gi 
signaling. (Mean ± SEM; NS P>0.05, ** P<0.005, * P<0.05; N=5-7/condition) 
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Figure 3.6 D2R TAT-TM5 disrupts the heteromeric Gq signaling of D2R-2AR in HEK293 
cells 
A. Bar graph summary of Gq activity measured in HEK293 cells expressing 2AR, incubated 4h 
with medium (vehicle) or 10 µM D2R TAT-TM5 peptide, in response to 0.1 µM 5-HT.  
B. Bar graph summary of Gq activity measured in HEK293 cells expressing 2AR and D2R, 
incubated 4 h with medium (vehicle), 10 µM D2R TAT-TM5 peptide, and 10 µM D2R TAT-
TM7 peptide, respectively, in response to 10 µM DA.  
D2R TAT-TM5 peptide significantly reduces the Gq trans-signaling in response to DA (B) 
without inhibiting 2AR homomeric Gq signaling in response to 5-HT (A). (Mean ± SEM; *** 
P<0.0005; N=8/condition) 
 
 
 
 
                      A                                                                      B 
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Figure 3.7 D2R TAT-TM5 disrupts field Excitatory postsynaptic potential (fEPSP) in PFC 
neurons 
(in collaboration with Sidiropoulou lab) 
A. Representative fEPSP trace in response to no ligand (control), 5-HT, 5-HT and DA, 
respectively. 
B. Bar graph summary showing the fEPSP of PFC neurons is significantly increased in response 
to co-addition of DA and 5-HT, which is reversed by D2R TM5 but not TM7 peptide.  
 
 
 
 
 
                                                  A 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               B 
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Figure 3.8 D2R TAT-TM5 disrupts DA desensitization in VTA neurons 
(In collaboration with Brodie lab) 
A. Dopamine administration inhibits the neuron firing rate. Prolonged exposure to DA (25 min 
wash with DA plus water) reversed the inhibition of neuron firing rate (Dopamine Inhibition 
Reversal) upon DA administration at 30 min and 45 min. 
B. The change of neuron firing rate upon DA administration is decreased with time (blue), which 
is abolished by treatment of D2R TM5 peptide (red).  
 
 
 
 
                                      A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      B 
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Figure 3.9 A mini gene method to disrupt the D2R-2AR heteromer 
A. Construct map of the D2R TM5 inserted in pXoom vector, preceded by the first 45 aa of the 
rat somatostatin receptor 3 (sstr3). 
B. Co-expression of the D2R TM5 with D2R and 2AR abolished the Gi potentiation in response 
to DA. 
 
 
                                 A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               B. 
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Chapter 4. STRUCTURE MODEL OF D2R-2AR DEMONSTRATING ITS COUPLING 
MECHANISM 
 
 
 
4.1 Background introduction 
4.1.1 GPCR homodimer interface 
                  Since 2000 Palczewsk et al. solved the crystal structure of rhodopsin,1 over 200 
crystal structures of more than 50 GPCRs have been reported.2 Crystal structures of GPCRs have 
provided the structural basis and protein folding topology for GPCR high-order oligomerization. 
Analysis of crystallography of GPCRs by Katritch et al., Stevens et al., and Shang et al. suggests 
that all 7 TMs as well as helix H8 could be found in GPCR homodimer interface,3,4,5 among 
which two types of dimerization interfaces are predominant: one involves TM1, TM2 and H8, 
the other involves TM4, TM5 and TM6.6 Most frequently homodimerization interfaces are found 
to be symmetric TM1,2, H8-TM1,2, H8, TM4,5-TM4,5 and TM5,6-TM5,6.7 Meng et al. and 
Kaczor et al. used computational approaches to investigate the stability and dynamics of putative 
GPCR homodimers inferred by existing GPCR crystal structures.8.9 Their results are consistent 
with these major types of GPCR homodimer interfaces.  
 
4.1.2 Putative GPCR heteromer interface 
         Up to date, although 183 class A, B and C GPCRs were found to form heteromers,10 no 
crystal structure of GPCR heteromers has been solved. To investigate the dimerization interface 
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of GPCR heteromers, multiple methods have been applied, including disruptive peptides, genetic 
mutations and computational simulations. The results inferred by experimental and 
computational methods suggest two types of interaction upon GPCR heterodimerization. One is 
the transmembrane helix-helix interactions, the other is intracellular electrostatic interactions 
(Table 4.1).  
           The helix-helix interfaces of several GPCR heteromers have been determined using a 
disruptive peptide method, including 5HT2A-CB1, A2A-D2, AT1a-SCT, CRF1–OX1, D1-D3, and 
DOR-MOR (Table 4.1).11-17 The dimerization interface of mGlu2-5HT2A was identified by 
genetic mutation (chimera).18 A computational model was built for A2A-D2  and  mGlu2-5HT2A 
based on the experimental results (Figure 4.2), and for A1A-A2A, T1R2-T1R3, CXCR4-CCR2 
and CXCR4-CCR5 based on MD simulation.13,19-22 These results suggest that TM1, TM4, TM5 
and TM6 are hot spots for GPCR heterodimerization (Table 4.1). 
          In 2005, Woods et al. proposed a role for electrostatic interactions in GPCR 
heteromerization, in which positively charged residues of one protomer (usually a cluster of 
Arginine-rich (R-rich) epitope at IL3) interacts with negatively charged residue(s) of the other 
(could be a phosphorylated Ser (pS) or Thr (pT), or two adjacent Glu (EE) or Asp (DD) at the C-
terminus or IL3).23 Using mutagenesis methods combined with mass spectrometry and 
bioluminescence resonance energy transfer (BRET), Ciruela et al., Fernández-Dueñas et al., and 
Borroto-Escuela et al. showed that the interaction between positively charged R-rich residues at 
the IL3 of D2R and the negatively charged pS or DD residues at the C terminus of A2AR was 
necessary to the A2AR-D2R heteromer formation (Figure 4.3).24-26 This type of electrostatic 
interaction has also been found necessary to the heteromerization of A2A-CB1, D1-D2, CB1-D2  and 
GRPR-MOR (Table 4.1).23,27-29 
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4.1.3 The R-rich motif at IL3 of D2R is necessary for the co-localization of D2R and 2AR 
          The heteromeric dimerization interface of D2R-2AR putative heteromer has not been 
reported. In 2010, using confocal microscopy and mutagenesis methods, Borroto-Escuela et al. 
investigated the role of positively charged R-rich residues (217RRRRKR222) at IL3 of D2R and 
negatively charged glutamate residues (454EE455) at the C-terminus of 2AR in the formation of 
heteromeric complex between D2R and 2AR.30 Their results showed that in cells co-expressing 
D2R and 2AR, these two receptors were found to co-localize at the plasma membrane and within 
the cells, whereas mutating the R-rich residues of D2R to alanine significantly decreased the co-
localization between D2Rmut and WT 2AR, indicating that the R-rich motif at IL3 of D2R is 
necessary to the co-localization and possibly heteromeric formation of D2R and 2AR (Figure 
4.4).  
 
4.14 Aims 
        The bimolecular fluorescence complementation (BiFC) data with peptides from our 
collaborating Ferré lab indicate TM5 and TM6 of D2R or 2AR are involved in the D2R-2AR 
heteromeric interface. In this study, we aim to present both functional data and evidence towards 
the structural basis of the coupling mechanism of the D2R-2AR heteromer. We first aim to 
identify residues on the heteromeric interface and provide direct evidence that these residues are 
necessary to the heteromeric signaling of D2R-2AR heteromer. We further aim to build a 
structural model of D2R-2AR that recapitulates the functional cross-talk between D2R and 2AR 
and offers insights to the structural coupling mechanism between these two receptors.   
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4.2 Results and discussion 
4.2.1 Pi-Pi stacking interaction among conserved aromatic residues 5.47, 5.48, 6.51 and 6.52 
         To identify the residues involved in helix-helix interaction of D2R-2AR, I aligned the TM5 
and TM6 of all dopamine receptors, serotonin type 2 receptors, and five class A GPCR receptors 
that form heteromers with D2R. The sequence alignment shows that residues at position 5.47, 
5.48, 6.51 and 6.52 are conserved aromatic residues, either phenylalanine (F) or tyrosine (Y) 
(Figure 4.5A). Crystal structures have been reported for D2R (PDB ID 6C38) and 2CR (or 5-
HT2CR) (PDB ID 6BQH) in their inactive states.31,32 The conformation of the four conserved 
aromatic residues in the structures of D2R and 2CR indicates edge-to-face Pi-Pi stacking 
interactions between residues 5.48 and 5.47, 6.52 and 6.51, and face-to-face Pi-Pi stacking 
interactions between residues 5.47 and 6.52 (Figure 4.5B). Measurement in Pymol shows that 
the distance between the closest carbon atoms of two adjacent aromatic rings are within the 3.4 
Å-4.1Å range (Figure 4.5B), which allows the Pi-Pi stacking interaction to form between two 
proximal aromatic rings. This conformation information extracted from the crystal structures of 
D2R and 2CR suggests a network of Pi-Pi stacking interaction among residues 5.48, 5.47, 6.52 
and 6.51; if the conformation of any residue changes, the conformation of the others may change 
accordingly. Considering 2AR and 2CR are in the same subfamily and have high similarity, 
presumably it is the same case for residues 5.48, 5.47, 6.52 and 6.51 of 2AR. 
 
4.2.2 The role of residues 6.51 and 6.52 in agonist binding and receptor activation 
         Wacker et al. solved the crystal structure of 2CR binding to the agonist ergotamine and 
inverse agonist ritanserin.32 According to their results, the ergoline ring of the ergotamine stacks 
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against and forms Pi-Pi stacking interactions with F6.51 and F6.52 of 2CR (Figure 4.6). Given 
that dopamine and serotonin share the same backbone with the ergoline core and based on 
published pharmacology results, F6.51 and F6.52 of D2R and 2AR form Pi-Pi stacking 
interactions with dopamine and serotonin respectively as well.33-35 Upon agonist binding, the 
conformation change of F6.51 and F6.52 leads to the conformation changes of nearby P6.50.36 
The rotation of the conserved proline further triggers the global rotamer toggle switch, which is 
the most common mechanism of GPCR activation, with W6.48 (in the CWxxP motif) moving 
down, and the F6.44 and I3.40 (in the W-I-F motif) switching their upper and lower positions 
(Figure 4.6), resulting in the breakage of the ionic lock (between R3.50 and E6.30) and receptor 
activation.32,36,37  
 
4.2.3 The 5.48 residue is localized at the outer surface of the helical bundle 
         The crystal structures of D2R and 2CR show that the four conserved aromatic residues are 
at the same height as the orthosteric ligand-binding sites. Among them, only the residues at 
positions 5.48 are localized at the outer surface of the helical bundle, the other three residues are 
all embedded in the binding pocket inside the helical bundle (Figure 4.7). Snapshots of D2R and 
2CR crystal structures from a top view indicate that Y5.48 of D2R and F5.48 of 2CR could form 
face-to-face Pi-Pi stacking, if D2R and 2CR co-localize and interact through the TM5,6-TM5,6 
interface, forming a network of Pi-Pi stacking interaction among eight aromatic residues. When 
agonist binds to one receptor, the conformation of residues 6.51 and 6.52 will change. The 
network of Pi-Pi stacking interactions connected by residues 5.48 would enable this 
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conformational change to transfer to residues 6.51 and 6.52 of the partner receptor, thus resulting 
in the activation of the partner receptor.  
 
4.2.4 Hypothesis of the coupling mechanism of D2R-2AR heteromer 
         Based on the structural conformation of the four conserved aromatic residues and the role 
of residues 6.51 and 6.52 in agonist binding and receptor activation, I proposed the hypothesis 
for the coupling mechanism of D2R-2AR putative heteromer: D2R and 2AR heteromerize 
through symmetric TM5,6-TM5,6 interface with the 5.48 residues forming Pi-Pi stacking 
interactions. The 5.48 residues would enable the cross-talk between D2R and 2AR by 
transmitting energy and conformation change from one receptor to the other through the network 
of Pi-Pi stacking interactions. 
          To test this hypothesis, I mutated the 5.48 residues to make D2R(Y1995.48L) and 
2AR(F2445.48L) mutants, and expressed them alone or with the WT partner receptor to assess 
their role in D2R-2AR functional cross-talk.  
 
4.2.5 D2R(Y1995.48L) abolishes the Gi signaling functional cross-talk 
         D2R(Y1995.48L) was expressed alone or with WT 2AR in oocytes (Figure 4.8). The Gi 
activity of D2R(Y1995.48L) is comparable with that of the WT D2R, indicating this mutant is 
functional. The Gi activity in response to 1 µM DA measured in D2R(Y1995.48L) and 2AR co-
expression is significantly decreased compared to D2R and 2AR co-expression but similar to 
D2R alone, suggesting that D2R(Y1995.48L) abolished the Gi cis-signaling enhancement shown in 
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the D2R-2AR heteromer. More strikingly, remarkable Gi activity reduction was observed in 
response to 10 µM 5-HT in oocytes co-expressing D2R(Y1995.48L) and 2AR, indicating the Gi 
trans-signaling is also abolished. These results suggest that the single mutation of 
D2R(Y1995.48L) abolishes the Gi signaling functional cross-talk between D2R and 2AR.  
 
4.2.6 2AR(F2445.48L) abolishes the Gi signaling functional cross-talk 
         2AR(F2445.48L) was expressed alone or with WT D2R in HEK293E cells (Figure 4.9). 
2AR(F2445.48L) gave comparable Gi activity comparable with WT 2AR, indicating this mutation 
does not affect the function. The Gq activity in response to 0.1 µM 5-HT obtained in cells co-
expressing 2AR(F2445.48L) and D2R is significantly decreased compared with cells co-
expressing WT 2AR and D2R but similar with cells expressing 2AR alone, suggesting that 
2AR(F2445.48L) abolished the Gq cis-signaling enhancement shown in D2R-2AR heteromer.  
Remarkable Gq activity reduction was observed in response to 10 µM DA cells co-expressing 
2AR(F2445.48L) and D2R, indicating the Gq trans-signaling is also abolished. These results 
suggest that the single mutation of 2AR(F2445.48L) abolishes the Gq signaling functional cross-
talk between D2R and 2AR. 
 
4.2.7 Computational model of D2R-2AR 
         The fluorescence complementation data from Dr. Ferré lab and our mutagenesis data 
suggest the involvement of TM5 and TM6 in the D2R-2AR heteromeric interface. Based on these 
results, Dr. Meng Cui in the Logothetis lab built a computational model of the D2R-2AR 
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heteromer recapitulating its functional cross-talk. In 2012, Manglik et al. reported the crystal 
structure of the Mu opioid receptor (MOR), and demonstrated that MOR homomer dimerizes 
through symmetric TM5,6-TM5,6 interface.38 Cui et al. superimposed the structure of D2R and 
2AR into the structure of MOR dimer and obtained the model of D2R-2AR heteromer (Figure 
4.10).  The structures of D2R and 2AR fit well into the structure of MOR dimer without showing 
collision at TM5 or TM6. Measurement in PyMol shows that the most stable conformation of 
D2R(Y1995.48) and 2AR(F2445.48) is observed when their aromatic rings are positioned parallel, 
with the distance of 4.7 Å between the closest carbon atoms of the two rings. According to the 
PDB protein database, the maximal distance for parallel Pi-Pi stacking is 5.99 Å. Thus, in the 
D2R-2AR model, the 5.48 residues of D2R and 2AR form face-to-face Pi-Pi stacking interaction. 
In the Molecular Dynamic simulation of the D2R-2AR model, the conformation change of the 
eight conserved aromatic residues of D2R and 2AR are synergized, clearly showing the network 
of Pi-Pi stacking interaction among these residues. MD simulation is underway to monitor 
whether a receptor protomer will be activated after adding the agonist of the partner receptor.  
 
4.2.8 The positively charged R-rich motif is necessary to the heteromer formation between 
dopamine receptor and 2AR 
         Sequence alignment of mouse Dopamine D2 Receptor (mD2R), human Dopamine D3 
Receptor (hD3R) and human Dopamine D4 Receptor (hD4R) shows that hD3R has a R-rich motif 
at the same position as mD2R (at the beginning of IL3) whereas the R-rich motif of hD4R is 
removed to a different location (at the C-terminal end of IL3). D3R with 2AR and D4R with 2AR 
were co-expressed in oocytes respectively to assess whether they can form heteromers by 
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exhibiting functional cross-talk (Figure 4.11). The Gi activity enhancement was observed in 
oocytes co-expressing D3R and 2AR in response to 1 µM DA and co-addition of 1 µM DA and 
1 µM 5-HT, but not in oocytes co-expressing D4R and 2AR, indicating heteromer formation 
between D3R and 2AR but not D4R and 2AR. Introducing the R-rich motif to the N-terminal end 
of IL3 at D4R enabled the Gi signaling functional cross-talk between D4R(RKRRKR) and 2AR, 
indicating the R-rich motif is necessary to the heteromer formation between dopamine receptor 
and 2AR. 
 
4.2.9 The electrostatic interaction between the R-rich residues of D2R and the EE residues of 
2AR is necessary for the D2R-2AR heteromeric signaling 
         To determine whether the R-rich residues of D2R form electrostatic interaction with the EE 
residues of 2AR, the 217RKRRKR222 and three additional 267RRR269 at IL3 of D2R were mutated 
to alanine to make the D2R(9A) mutant.  Additionally, the 454EE455 at the C-terminus of 2AR 
were mutated to alanine to make the 2AR(2A) mutant (Figure 4.12). Co-expression of D2R(9A) 
and 2AR showed no Gi activity enhancement in response to either DA or co-addition of DA and 
5-HT; similarly, co-expression of D2R and 2AR(2A) showed no Gq activity enhancement in 
response to either 5-HT or co-addition of DA and 5-HT, suggesting the functional cross-talk 
between D2R and 2AR is abolished by either D2R(9A) or 2AR(2A) mutation. These results 
indicate that likely electrostatic interactions involving the positively charged cluster of R-rich 
residues at the IL3 of D2R and the negatively charged EE residues at the C terminus of 2AR are 
critical for D2R-2AR heteromer cross signaling. 
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4.3 Summary 
In the experiments summarized in this chapter, we identified residues on TM5 of D2R 
and 2AR that are necessary to D2R-2AR heteromeric signaling. We showed intracellular residues 
important for the heteromeric formation of D2R-2AR. We proposed a coupling mechanism for 
D2R and 2AR and built a computational model of D2R-2AR heteromer that recapitulates its 
functional cross-talk. We summarize the results and conclusions as follows: 
1. D2R(Y1995.48) and 2AR(F2445.48) are necessary to D2R-2AR heteromeric signaling. 
2. D2R and 2AR heteromerize through a symmetric TM5,6-TM5,6 interface. 
3. The network of Pi-Pi stacking interactions among residues 5.47, 5.48, 6.51 and 6.52 of 
D2R and 2AR may underlie the mechanism for the functional cross-talk between D2R and 2AR. 
4. Electrostatic interactions involving the R-rich motif at IL3 of D2R and EE residues at 
C-terminus of 2AR are important for D2R-2AR heteromer signaling.  
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Figure 4.1 Putative GPCR homodimer interfaces inferred by existing crystal structures 
Dimers are boxed (gray color) according to interface type. Protein name and interface type are 
reported under each dimeric structure. PDB ID and interface area are included in parenthesis. 
Adapted from Shang et al., Eur J Pharmacol (2015) 
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Table 4.1 Putative GPCR heterodimer interface inferred by disruptive peptides, genetic 
mutation, and computational methods 
P=disruptive peptide 
M=genetic mutation or chimera 
C=computational simulation 
 
 
Transmembrane helix-helix interaction 
Complex Helical interface Method Reference 
5HT2A-CB1 TM5,6-TM5,6  P 1 
A1A-A2A TM4,5-TM4,5  C 2 
A2A-D2 TM4,5-TM4,5  P, C 3, 4, 5 
AT1a-SCT AT1a TM1  P 6 
CRF1–OX1 OX1 TM1,5  P 7 
D1-D3 D1 TM5,6  P 8 
DOR-MOR MOR TM1  P 9 
mGlu2-5HT2A TM4-TM4  M, C 10, 11 
T1R2-T1R3 TM5,6-TM5,6  C 12 
CXCR4-CCR2 TM1-TM1  C 13 
CXCR4-CCR5 TM1-TM4,5  C 13 
 
 
Intracellular electrostatic interaction 
 
 
 
 
 
 
Complex Positively   Negative Method Reference 
A2A-CB1 A2A IL3 RR CB1 CT pTpS  M 14 
A2A-D2 D2 IL3 RRRRKR or RRR A2A CT pS or DD  M, P 3, 14, 15, 16, 17 
D1-D2 D2 IL3 RRRRKR or RRR D1 CT EE  P 18, 19 
CB1-D2 D2 IL3 RRRRKR CB1 IL3 pTpS  M 14 
GRPR-MOR1D GRPR IL3 RKR MOR1D CT EE  P 20 
1. Viñals	et	al.,	2014	
2. Navarro	et	al.,	2016	
3. Borroto-Escuela	et	al.,	2010	
4. Bonaventura	et	al.,	2015	
5. Navarro	et	al.,	2018	
6. Lee	et	al.,	2014	
7. Navarro	et	al.,	2015	
8. Guitart	et	al.,	2014	
9. He	et	al.,	2011	
10. Moreno	et	al.,	2012	
11. Moreno	et	al.,	2016	
12. Kim	et	al.,	2017	
13. Gahbauer	et	al.,	2018	
14. Ciruela	et	al.,	2004	
15. Azdad	et	al.,	2009	
16. Navarro	et	al.,	2010	
17. Fernández-Dueñas	et	al.,	2012	
18. Pei	et	al.,	2010	
19. Hasbi	et	al.,	2014	
20. Liu	et	al.,	2011	
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Figure 4.2 Putative heterodimer helical interface of A2AR-D2R and mGlu2-2AR 
A. Computational model of A2AR-D2R showing A2AR and D2R dimerize through TM4,5-TM4,5 
interface, based on results obtained using disruptive peptide (Figure 2.3). 
Adapted from Navarro et al., Nature Communication (2018) 
B. Computational model of mGlu2-2AR showing mGlu2 and 2AR dimerize through TM4-TM4 
interface, based on Co-IP results obtained with chimera. 
Adapted from Moreno et al., Science Signaling (2014) 
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Figure 4.3 The electrostatic interaction between the positively charged cluster of R-rich 
residues at the IL3 of D2R and the negatively charged pS or DD residues at the C terminus 
of A2AR is necessary to the A2AR-D2R heteromer formation 
a. Schematic showing the D2R mutation locates at the third intracellular loop 3 (IL3). 
b. BRET saturation curves of A2ARRluc/D2RYFP (red) and A2ARRluc/ D2RmutYFP (blue)  
c. Bar graph summary of (b) and negative control. Values represent percentages of maximal 
saturable BRET responses (BRETmax). *** p < 0.001, +++ p < 0.001. 
Adapted from Fernández-Dueñas V et al., J Neurochem (2012) 
d. BRET saturation curves of A2AR and D2R compared to indicated D2R–A2AR mutant hetero-
oligomers. *** P < 0.001, * P < 0.05.  
Adapted from Borroto-Escuela et al., BBRC (2010) 
e. Mass spectrometry results showing the formation of peptide-peptide complex. 
Adapted from Ciruela et al., Analytic Chemistry (2004).  
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Figure 4.4 The R-rich motif at IL3 of D2R is necessary to D2R and 2AR co-localization 
A. Confocal microscopy images of HEK293 cells co-transfected with either 5-HT2A-CFP or 5-
HT2AMUT-CFP and either D2-YFP, D2R1-YFP, D2R2-YFP, D2R3-YFP or 5-HT2A-YFP (green 
and red).  
B. Bar graph of Pearson's correlation coefficient calculated for HEK293 cells co-transfected with 
indicated serotonin 5-HT2A and dopamine D2 receptor construct combination. *p<0.05  
Adapted from Borroto-Escuela et al., BBA (2010) 
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Figure 4.5 Pi-Pi stacking interaction among conserved aromatic residues 5.47, 5.48, 6.51 
and 6.52  
A. and B. TM5 and TM6 alignment of dopamine receptors, serotonin type 2 receptors and five 
receptors that form heteromer with D2R. The 5.47, 5.48, 6.51 and 6.52 residues are conserved 
aromatic residues (highlighted in pink). The residue positions are numbered according to the 
Ballesteros-Weinstein numbering scheme. 
C. and D. Crystal structure of D2R and 2CR showing the four conserved aromatic residues 
(shown as sticks) form either edge-to-face or face-to-face Pi-Pi stacking interaction (helical 
structure of the receptor is hidden for better visibility of the aromatic residues). The distance 
between the closest carbon atoms of two adjacent aromatic rings are shown and measured in 
PyMOL. PDB ID is included in parenthesis.  
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Figure 4.6 The role of residues 6.51 and 6.52 in agonist binding and receptor activation 
A. The ergoline core of ergotamine in the structures of 5-HT2C (orange), 5-HT1B (light blue; 
PDB: 4IAR), and 5-HT2B (yellow; PDB: 4IB4). Key residues that recognize and interact with 
the ergoline core are labeled and shown as sticks. Residues 6.51 and 6.51 (circled in red) form 
Pi-Pi stacking interaction with the ergoline ring. 
B. The conformational changes of F3376.51 and F3386.52 upon agonist binding potentiates the 
conformational changes of W3246.48, I1423.40 and F3206.44 in the W-I-F motif (rotamer 
toggle switch), leading to the opening of ionic lock and receptor activation. 
Adapted from Peng et al., Cell (2018) 
C. Chemical structures of ergotamine, DA and 5-HT showing DA and 5-HT have the same 
backbones as ergotamine (highlighted in blue).  
Adapted from Wacker et al., Cell (2017) 
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Figure 4.7 The 5.48 residues are localized at the outer surface of the helical bundle  
A. and B. Side view of D2R (A) and 2CR (B). The 5.47, 6.51 and 6.52 residues are embedded in 
the binding pocket in the helical bundle. 5.48 residue (labelled) locates at the out surface of the 
helical bundle and points toward TM6. 
C. Top view of D2R and 2CR (horizontally flipped). The 5.48 residues of D2R and 2CR could 
form face-to-face Pi-Pi stacking if D2R and 2CR co-localize and interact through the TM5-TM6 
interface, forming a network of Pi-Pi stacking interaction among eight aromatic residues.  
The four conserved aromatic residues are shown as sticks. Structure of receptor is shown as 
cartoon. PDB ID is included in parenthesis. 
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Figure 4.8 D2R(Y1995.48L) abolishes the Gi signaling functional cross-talk  
Bar graph summary of Gi activity showing co-expression of D2R(Y199L) with 2AR abolishes 
the Gi cis-signaling potentiation in response to 1 µM DA and Gi trans-signaling in response to 
10 µM 5-HT which is observed in co-expression of WT D2R with 2AR, while the Gi activity of 
D2R(Y199L) is comparable to WT D2R. (Mean ± SEM; ** P<0.005; N=6-7/condition) 
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Figure 4.9 2AR(F2445.48L)	abolishes	the	Gq	signaling	functional	cross-talk	
Bar graph summary of Gq activity showing co-expression of 2AR(F244L) with D2R abolishes 
the Gq cis-signaling potentiation in response to 0.1 µM 5-HT and Gq trans-signaling in response 
to 10 µM DA which is shown when WT 2AR is co-expressed with D2R, while 2AR(F244L) gave 
comparable response to 5-HT as WT 2AR. (Mean ± SEM; NS P>0.05, *** P<0.0005; N=8-
16/condition) 
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Figure 4.10 The TM5,6-TM5,6 dimerization interface of Mu-opioid receptor 
a. Schematic structure of the TM5,6–TM5,6 four-helix bundle interface.  
b. The tight association between the ligand (green sticks) in the bind pocket and residues that are 
involved in forming the dimeric interface (blue spheres) in the four-helix bundle. 
c. The interacting residues in the four-helix bundle (shown as sticks).  
d. The high surface complementarity within the four-helix bundle interface along the dimer 
interface (as indicated in panel c). 
Adapted from Manglik et al., Nature (2012) 
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Figure 4.11 Computational model of D2R-2AR recapitulating its functional cross-talk  
A. Crystal structure of MOR dimer. PDB ID 4DKL  
B. and C. Side view (B) and top view (C) of the D2R-2AR MD simulation model. The structure 
of D2R and 2AR is superimposed into the structure of MOR dimer.  D2R and 2AR dimerize 
through the TM5-TM6 interface. The distance between the closest carbon atoms of the 5.48 
residues is 4.7A° (at the beginning stage of simulation, measured in PyMOL). 
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Figure 4.12 The positively charged R-rich motif is necessary to DxR-2AR heteromer 
formation 
Bar graph summary of Gi activity showing functional cross-talk between D3R (with R-rich motif 
at the same position as D2R) and 2AR (A), and introducing the R-rich motif to the corresponding 
position of D4R enables the functional cross-talk between D4R and 2AR (B and C). (Mean ± 
SEM; NS P>0.05, * P<0.05, ** P<0.005, *** P<0.0005; N=5-12/condition) 
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Figure 4.13 Electrostatic interactions involving the positively charged cluster of R-rich 
residues at the IL3 of D2R and the negatively charged EE residues at the C terminus of 
2AR are critical for D2R-2AR heteromeric signaling 
Bar graph summary of Gi and Gq activity showing co-expression of D2R(9A) with 2AR, or D2R 
with 2AR(2A) abolished the Gi and Gq functional cross-talk observed in co-expression of WT 
D2R and 2AR. The 9A mutation locates at IL3 of D2R; The 2A mutation locates at C terminus of 
2AR. (Mean ± SEM; NS P>0.05, * P<0.05, ** P<0.005, *** P<0.0005; N=5-12/condition) 
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Chapter 5. EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS ON THE FUNCTION OF THE 
D2R-2AR HETEROMER 
 
 
5.1 Background introduction 
5.1.1 2AR is necessary to haloperidol’s full antipsychotic effectiveness  
         In an animal behavioral study, Albizu et al. used MK-801, an NMDA receptor antagonist to 
induce psychotic behavior in mice (Figure 1.6).1 The locomotor activity of mice was 
significantly increased following MK-801 injection, an effect that was reversed by 
administration of typical antipsychotic haloperidol (HLP). However, the effect of HLP to reduce 
MK-801 induced psychotic behavior was significantly attenuated in 2AR KO mice. It is known 
that HLP’s antipsychotic action is through D2R antagonism and it has low affinity to 2AR.2 The 
fact that HLP could still antagonize D2R in 2AR KO mice but is less efficacious suggests that 
2AR is necessary for HLP to exert its full antipsychotic effect. 
 
5.1.2 Combination of antipsychotic drugs (APDs) exerts enhanced antipsychotic effect and 
reduced side effect 
         Combinations of typical and atypical APDs are regularly prescribed for treatment of 
schizophrenia.3 The clinical benefits include: improvement in positive and negative 
symptoms, decreased total doses of medications, reduced extra-pyramidal side effects, weight 
gain and hyperprolactinemia.4   
         In a meta-analysis, Correl et al. (2008) evaluated antipsychotic combinations versus 
monotherapy in schizophrenia.5 11 Combination antipsychotics, including the use of 2 typical 
APDs, 2 atypical APDs, or 1 of each, were found to be more efficacious in producing a clinically 
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significant response than monotherapy. Among them combination of a typical and an atypical 
APD was found to be especially efficacious.  
          Pimavanserin, an atypical APD with high affinity for 2AR and no affinity for D2R was 
found to reduce psychotic behaviors (head twitches, hallucinations and delusions) and has 
completed Phase II trials for treatment of schizophrenia.6-11 In experimental model studies, 
combining high levels of PIMA and low levels of HLP or risperidone improved the antipsychotic 
efficacy and side effect profile of HLP and risperidone.12 In a large randomized controlled study 
of 423 patients, combining PIMA with low dose of risperidone or HLP augmented the efficacy 
of risperidone to a standard dose and reduced the side effects of risperidone and HLP.13 
 
5.1.3 Typical and atypical APDs potentiate the heteromerization of D2R-2AR 
         Lukasiewicz et al. assessed the role of APDs in D2R-2AR heteromerization.14,15 They 
applied the typical APD butaclamol and the atypical APD ketanserin to HEK cells co-expressing 
D2R and 2AR, and detected the heteromerization of D2R-2AR by FRET assay. Fluorescence 
signal detected from co-expression of D2R and 2AR was significantly increased with addition of 
butaclamol and ketanserin, indicating these APDs potentiate the heteromerization of D2R-2AR.  
          Interestingly, Lukasiewicz et al. also showed the typical APD haloperidol and the atypical 
APD ketanserin both decreased the homodimerization of 2AR.15 Although it has not been studied 
whether haloperidol or ketanserin decreases the homodimerization of D2R, Marsango et al. found 
that the typical APDs haloperidol and spiperone increased the distance between carbon atoms at 
D3R homomeric interface thus disrupted the homodimerization of D3R.16 These results indicate a 
potential feature of typical and atypical APDs in potentiating the heterodimerization of D2R-2AR 
and disrupting the homodimerization of D2R and 2AR.  
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5.1.4 Aims 
         In this study, we aim to investigate the effectiveness of antipsychotic drugs on the function 
of the D2R-2AR heteromer. We will compare the action of typical and atypical APDs on the D2R 
and 2AR homomers versus D2R-2AR heteromer, explore whether the effectiveness of APDs on 
D2R-2AR heteromer is dependent on the cross-talk between D2R and 2AR, and assess whether a 
combination of typical and atypical APDs on the D2R-2AR heteromer potentiates their 
effectiveness.  
 
5.2 Results and discussion 
5.2.1 The potency of HLP antagonizing DA is enhanced by the D2R-2AR heteromer 
         To assess whether the D2R-2AR heteromer plays a role in the action of typical 
antipsychotic drug, six doses of HLP were applied with 1 µM DA to oocytes expressing D2R 
alone or D2R with 2AR (Figure 5.1). Previous results showed that the potency of DA is similar 
on the D2R homomer and the D2R-2AR heteromer (Figure 2.4). Here, the dose-response curve 
of D2R+2AR is significantly left shifted compared with D2R, indicating HLP is more potent in 
antagonizing DA acting at the D2R-2AR hoteromer than the D2R homomer.  The IC50 values 
showed that the potency of HLP antagonizing DA acting at D2R+2AR was 11-fold greater than 
that on D2R. At 0.01 nM, HLP’s antagonism on D2R and D2R+2AR was negligible, thus the DA 
induced Gi signaling of D2R+2AR was two-fold of D2R. At 1 nM, HLP blocked half of the Gi 
signaling of D2R+2AR, whereas it showed little antagonism on D2R, resulting in similar Gi 
signaling in response to DA. Between the 1 nM to 1 µM range, with HLP antagonizing DA, the 
Gi signaling of D2R+2AR was significantly lower than D2R. The negative values of Gi activity 
in response to high doses of HLP exhibits HLP’s function as inverse agonist. 
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         The results that HLP is more potent in antagonizing DA acting at the D2R-2AR heteromer 
could lead to a greater relative potency of HLP in vivo, which may explain the behavioral results 
of Albizu et al. that 2AR is necessary for HLP’s full antipsychotic effect. A rational reasoning of 
these results is that HLP has higher binding affinity for the D2R-2AR heteromer than the D2R 
homomer, thus a lower dosage of HLP is needed to achieve the antipsychotic effect through the 
function of the D2R-2AR heteromer.  
 
5.2.2 The enhanced potency of HLP antagonizing DA depends on the cross-talk between D2R 
and 2AR through the 5.48 residue 
          Because HLP is more potent in antagonizing DA acting at the D2R-2AR heteromer, the  
Gi signaling of D2R+2AR in response to 100nM HLP+1uM DA is markedly lower than D2R. To 
assess whether the enhanced potency of HLP is dependent on the cross-talk between D2R and 
2AR, 100nM HLP+1uM DA was applied to oocytes co-expressing D2R(Y199L) and 2AR 
(Figure 5.2). The results show the Gi signaling of D2R(Y199L)+2AR is significantly higher than 
D2R+2AR and relatively close to D2R, suggesting that the enhanced potency of HLP 
antagonizing DA is attenuated when the cross-talk between D2R and 2AR is abolished. Control 
experiments with D2R(Y199L) homomer and D2R+2AR(F244L) are pending.  
 
5.2.3 The potency of HLP antagonizing Gq signaling is enhanced in the D2R-2AR heteromer 
         In Figure 2.11B we showed HLP decreased Gq signaling of D2R+2AR. We further assess 
whether HLP antagonizes 5-HT acting on the 2AR homomer by applying HLP doses with 
0.1 µM 5-HT to HEK cells expressing 2AR alone (Figure 5.3). The results show HLP decreases 
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Gq signaling of 2AR in a dose-dependent manner, but the potency is halved compared with 
D2R+2AR, as the IC50 values indicate. At 1 mM, the highest soluble concentration, HLP blocked 
almost 90% of the Gq signaling of D2R+2AR whereas it only reduced 60% of the Gq signaling 
of 2AR homomer. These results suggest HLP above micromolar concentrations acts as an 
antagonist to both 2AR homomer and D2R-2AR heteromer, and it is more potent in antagonizing 
the heteromer. Given the fact that HLP has markedly higher affinity to D2R than 2AR, it is 
possible that HLP decreases the Gq signaling of D2R-2AR through antagonism on D2R rather 
than compete binding with 5-HT.  
 
5.2.4 The enhanced potency of HLP antagonizing Gq signaling depends on the cross-talk 
between D2R and 2AR through the 5.48 residue 
         Because HLP is more potent in antagonizing D2R-2AR heteromer, the Gq signaling of 
D2R+2AR in response to 100 µM HLP+0.1 µM 5-HT is significantly lower than 2AR. To assess 
whether the enhanced potency of HLP antagonizing Gq signaing is dependent on the cross-talk 
between D2R and 2AR, 100 µM HLP+0.1 µM 5-HT was applied to HEK cells co-expression 
D2R and 2AR(F244L) (Figure 5.4). The results show Gq signaling of D2R+2AR(F244L) is 
significantly higher than D2R+2AR but comparable to 2AR, suggesting the enhanced potency of 
HLP antagonizing Gq signaling is reversed when the cross-talk between D2R and 2AR is 
abolished. Control experiments with 2AR(F244L) homomer and D2R(Y199L)+2AR are pending. 
 
5.2.5 Pimavanserin cross-talks to antagonize D2R 
         Previous work by Younkin et al. showed PIMA antagonized the Gq signaling of 2AR 
homomer and had no effect on antagonizing the Gi signaling of D2R homomer (Figure 5.5A).  In 
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oocytes co-expressing D2R and 2AR, 5 µM PIMA reversed the Gi signaling enhancement in 
response to 1 µM DA (Figure 5.5B). Considering that typical and atypical APDs such as 
butaclamol and ketanserin potentiate the formation of D2R-2AR heteromer, we anticipate that 
PIMA also potentiates the D2R-2AR heteromer rather than disrupting the heteromer. Thus, we 
conclude from these results that the reversed Gi signaling of D2R+2AR is due to PIMA cross-
talks to antagonize D2R. We will further perform full-dose responses of PIMA antagonizing the 
Gi signaling of D2R+2AR.   
         To assess whether PIMA’s antagonism on D2R is dependent on the cross-talk between D2R 
and 2AR, we will apply 5 µM PIMA with 1 µM DA to oocytes expressing D2R(Y199L) and 
D2R(Y199L)+2AR. Furthermore, we will assess whether PIMA is more potent in antagonizing 
D2R-2AR heteromer than 2AR homomer by applying PIMA doses with 0.1 µM 5-HT in HEK 
cells expressing 2AR and 2AR+D2R.  
         The results showing PIMA cross-talks to antagonize D2R (Figure 5.5) and HLP cross-talks 
to antagonize 2AR (Figure 5.3) bring up the possibility that the effectiveness of these two APDs 
may be altered or potentiated upon co-administration. Clinical use of antipsychotic combinations 
also suggests augmentation and possible interplay of APDs. It would be interesting to know 
whether PIMA would increase the potency of HLP antagonizing the D2R-2AR heteromer and 
vice versa. To meet this aim, we will consider concurrently applying low concentrations of 
PIMA with HLP doses and DA to oocytes co-expressing D2R and 2AR and low concentration of 
HLP with PIMA doses and 5-HT to HEK cells co-expressing D2R and 2AR, to assess the effect 
of combining typical and atypical APDs on the D2R-2AR heteromer.  
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5.3 Summary 
               
         In the experiments discussed in the chapter, we obtained dose-response curves of HLP 
acting on the D2R homomer, the 2AR homomer, and the co-expression of D2R and 2AR. We 
assessed the dependency of HLP’s effectiveness on the cross-talk between D2R and 2AR. We 
showed PIMA’s antagonism on the Gi signaling of D2R-2AR. We summarize the results and 
conclusions as follows: 
1. HLP is more potent in antagonizing DA acting on the D2R-2AR heteromer than the D2R 
homomer. 
2. HLP’s enhanced antagonism on Gi signaling is dependent on the cross-talk between D2R 
and 2AR. 
3. HLP is more potent in antagonizing the Gq signaling of D2R-2AR heteromer than 2AR 
homomer. 
4. HLP’s enhanced antagonism on Gq signaling is dependent on the cross-talk between 
D2R and 2AR. 
5. PIMA cross-talks to antagonize the Gi signaling of D2R-2AR. 
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Figure 5.1 The potency of HLP antagonizing DA is increased on the D2R-2AR heteromer  
A. Representative barium-sensitive traces of GIRK4* currents obtained in response to addition 
of 10 nM HLP (5 min or till current stabilizes), and 1 µM DA in oocytes expressing D2R alone 
(left panel), D2R with 2AR (right panel). (orange: outward current; blue: inward current) 
B. Dose-response curves showing the potency of HLP antagonizing DA at oocytes co-expressing 
D2R and 2AR (yellow) is increased by 11-fold compared with oocytes expressing D2R alone 
(black). Gi activity (GIRK4* current activation) was measured relative to the basal currents and 
was normalized relative to the Gi activity of D2R in response to 1 µM DA in the absence of HLP 
(100% or 1). RGS2 was co-injected to inhibit Gq signaling. (Mean ± SEM; N=6-12/condition) 
 
 
 
         A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             B 
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Figure 5.2 The increased potency of HLP antagonizing DA depends on the cross-talk 
between D2R and 2AR through 5.48 residue 
A. Representative barium-sensitive traces of GIRK4* currents obtained in response to 10 nM 
HLP, and 1 µM DA in oocytes expressing D2R(Y199L) with 2AR. (orange: outward current; 
blue: inward current) 
B. Bar graph summary showing the Gi activity obtained in response to 1 µM DA after addition 
of 10 nM HLP in oocytes expressing D2R alone, D2R with 2AR, and D2R(Y199L) with 2AR, 
respectively. Gi activity (GIRK4* current activation) was measured and normalized as Figure 
5.1. RGS2 was co-injected to inhibit Gq signaling. (Mean ± SEM; * P<0.05, **** P<0.0001; 
N=9-15/condition) 
 
A 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 5.3 The potency of HLP antagonizing Gq signaling is increased on the D2R-2AR 
heteromer 
Dose-response curves showing the potency of HLP antagonizing 5-HT at HEK293E cells co-
expressing D2R and 2AR (red) is enhanced compared with cells expressing 2AR alone (black). 
Gq activity was measured relative to the basal fluorescence and was normalized relative to the 
Gq activity of 2AR in response to 0.1 µM 5-HT in the absence of HLP (100). (Mean ± SEM; 
N=4-9/condition) 
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Figure 5.4 The increased potency of HLP antagonizing Gq signaling depends on the cross-
talk between D2R and 2AR through 5.48 residue 
Bar graph summary showing the Gq activity obtained in response to co-addition of 0.1 µM 5-HT 
and 100 µM HLP in HEK293E cells expressing 2AR alone, D2R with 2AR, and D2R(Y199L) 
with 2AR, respectively. Gq activity was measured and normalized as Figure 5.3. (Mean ± SEM; 
** P<0.005, **** P<0.0001; N=4-14/condition) 
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Figure 5.5 Pimavanserin cross-talks to antagonize D2R 
A. Gi signaling (yellow) in response to co-addition of PIMA doses with 1 µM DA in oocytes 
expressing D2R alone and Gq signaling (red) in response to co-addtion of PIMA doses with 1uM 
5-HT in oocytes expressing 2AR alone. Dash line represents Gi and Gq activity in response to 
1 µM DA or 5-HT.  
B. Bar graph summary showing 5 µM PIMA reversed the Gi signaling enhancement in response 
to 1 µM DA in oocytes co-expressing D2R and 2AR whereas the D2R homomeric Gi signaling is 
not affected.   
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B 
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Chapter 6. DISCUSSION AND CONCLUDING REMARKS 
 
 
 
6.1 Is D2R-2AR officially a heteromer? 
         
           Over the last decade, many GPCR receptors have been reported to form receptor 
heteromers.1-4 Ferré at al. defined GPCR heteromer as a “macromolecular complex composed of 
at least two (functional) receptor units with biochemical properties that are demonstrably 
different from those of its individual components”.5 To fulfil this definition, evidence is needed 
that the receptors exist as a macromolecular complex and possess unique properties compared to 
the protomers. Many studies have assessed the formation of GPCR heteromers using 
recombinant receptors expressed in heterologous systems; however, only a few have 
demonstrated novel biochemical or physiological properties of these complexes in native tissues. 
In an annual review, Gomes et al. proposed the criteria to establish GPCR heteromers: “Criterion 
1: Heteromer components should co-localize and physically interact. Criterion 2: Heteromers 
should exhibit properties distinct from those of the protomers. Criterion 3: Heteromer disruption 
should lead to a loss of heteromer-specific properties.” (Figure 6.1 A)6 Reports on DOR-MOR, 
7-12 A2AR-D2R,13-21 D1R-D2R,22-26 α1A/BAR-CXCR4,27 and M1-M228,29 have fulfilled all three 
criteria to establish these heteromers in native tissue. 
           Our studies on D2R-2AR have fulfilled all three criteria to establish the D2R-2AR 
heteromers in heterologous systems. The bimolecular fluorescence complementation (BiFC) data 
from our collaborators (Ferré et al.) showed heteromerization of D2R-2AR in HEK293 cells. Our 
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oocyte and calcium mobilization data demonstrated unique pharmacological properties of D2R-
2AR distinct from each protomer. Applying disruptive peptides and genetic mutation methods, 
we showed disruption of D2R-2AR heteromeric complex and removal of D2R-2AR heteromeric 
signaling. 
           Published reports 30 and studies from our collaborators (Sidiropoulou and Brodie labs) 
have fulfilled criterion 1 and 2 to establish D2R-2AR heteromer in native tissues. Using in situ 
proximity ligation assay,30 Borroto-Escuela et al. revealed the existence of an endogenous D2R-
2AR complex in rat striatum. Brain slice data from our collaborating Sidiropoulou and Brodie 
labs exhibited the function of D2R-2AR in controlling the electrophysiological behavior of PFC 
and VTA neurons, respectively. Regarding the third criterion, our collaborating Gonzalez-Maeso 
lab is applying a disruptive peptide in an animal behavioral study to explore the effectiveness of 
antipsychotic drugs on the function of the putative native D2R-2AR heteromer. Thus, fulfilling 
all three criteria to establish the existence of the D2R-2AR heteromer in native tissue is pending 
on the animal behavioral results (Figure 6.1 B).  
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6.2 A common coupling mechanism for aminergic GPCR heteromers? 
 
 
 
           The studies in Chapter 4 suggest that a network of Pi-Pi stacking interaction among 
residues 5.47, 5.48, 6.51 and 6.52 may underlie the coupling mechanism for the D2R-2AR 
heteromer.  Alignment of all aminergic receptors reveals high conservation in residues 5.47, 
5.48, 6.51 and 6.52 (Figure 6.2). 31 out 44 receptors possess aromatic residues at these 
positions, including all dopaminergic receptors, serotoninergic receptors, adrenergic receptors, 2 
histaminergic receptors and 2 trace amine receptors. The high conservation of aromatic residues 
in aminergic receptors raises the question: could the coupling mechanism of the D2R-2AR 
heteromer be a common coupling mechanism for aminergic GPCR heteromers? 
           My speculation is based on the following reasons. TM5 and TM6 of aminergic GPCRs 
undergo significant conformational changes upon receptor activation and are key components for 
aminergic GPCRs activation.31-33 The residues 6.51 and 6.52 have been found to play important 
roles in agonist binding and receptor activation not only for dopaminergic and serotoninergic 
receptors but for all aminergic receptors.31-33 Among the 33 receptors with four conserved 
aromatic residues, 9 have been reported with solved crystal structure, including D2,34 D3,35 D4,36 
5HT1B,37 5HT2B,38-42 5HT2C,43 β1A,44-52 β2B,53-67 and H1.68 Examination of the crystal structures of 
these receptors reveals the formation of Pi-Pi stacking interaction among the residues 5.47, 5,48, 
6,51 and 6.52 of all 9 receptors in either active or inactive states, indicating that this Pi-Pi 
stacking in the cluster of aromatic residues is a common feature for aminergic GPCRs.  
Aminergic GPCRs are of critical importance as they are associated with various diseases 
and are the targets for 25% of current drugs.69 Many aminergic GPCR heteromers have been 
found to play an important role in psychiatric disorders, including D1-D2,70-74 D1-D3,75-76 D2-D3,77-
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79 D2s-D4,80 D1-H3, 81,82 D2-H3,83 α1B-D4,84, and β1A-D4 84. Determining the coupling mechanism of 
these heteromers and other potential aminergic GPCR heteromers is of great significance:  
1. It will help to understand and predict the integrated signaling of aminergic GPCR 
heteromers.  
2. It will motivate mutation at residues 5.48 as potential negative controls to assess the 
pharmacological and biochemical properties of aminergic GPCR heteromers.  
3. It will provide TM5 and TM6 as potential targets for the design of disruptive peptides 
to manipulate the formation and assess the physiological properties of aminergic GPCR 
heteromers.   
4. It will facilitate the design of heteromer-selective drugs specifically targeting the 
heteromeric interface of aminergic GPCR heteromers, therefore eliminating the side-effects of 
antipsychotic drugs, which in many cases are due to promiscuous interactions with proteins other 
than the intended target(s).86-90  
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6.3 Unifying model of D2R-2AR’s dual role in psychosis 
 
 
         Psychosis associated with schizophrenia shows alterations in the level of Gi signaling and 
Gq signaling.91 Postmortem studies have shown up-regulated D2R in the striatum and 2AR in 
cortical regions, leading to potentiation of both Gi and Gq signaling in psychosis compared to the 
physiological state.91-97  
         Our studies exhibit a dual role of the D2R-2AR heteromer in psychosis (Figure 6.3). Both 
Gi and Gq signaling are potentiated due to the functional cross-talk of D2R-2AR, thus shifting 
the balance from the physiological state to a psychotic state. In this sense, the D2R-2AR 
heteromer could be considered as a “bad” heteromer, as it promotes psychosis. On the other 
hand, antagonists of either D2R or 2AR could inhibit both receptors through the cross-talk 
between D2R and 2AR, and the effectiveness of both D2R and 2AR antagonists (typical and 
atypical antipsychotic drugs) is potentiated through the function of the D2R-2AR heteromer, thus 
reversing both Gi and Gq signaling potentiation and shifting the balance from a psychotic state to 
the physiological state. In this sense, the D2R-2AR heteromer could be considered as a “good” 
heteromer, as it would enhance the antipsychotic effect of APDs and reduce psychosis.  
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6.4 Putative bivalent ligands of the D2R-2AR heteromer 
 
 
Since 1986 with the first report of a bivalent ligand targeting opioid receptor dimers, the 
bivalent ligand approach has received increasing attention as new methods for validation of 
physical interactions and novel pharmacological and physiological properties of GPCR 
heterodimers.98,99 Moreover, the bivalent ligand approach has been widely used in therapeutic 
development for GPCR heteromers associated with drug tolerance and psychiatric diseases.99      
A number of bivalent ligands have been designed for GPCR heteromers, including µOR-
δOR,100,101 µOR-CB1,102  µOR-mGlu5,103 µOR-CCR5,104  δOR-κOR,105 µOR-NK1,106  MT1-
MT2,107 A2AR-D2R,108 and D2R-NTS1R.109   
Bivalent ligands are defined as compounds that contain two pharmacophore units linked 
by a spacer (Figure 6.4 A and B). The two pharmacophores can be either identical 
(homobivalent) or different (heterobivalent). The length of the spacer is adjustable to achieve 
optimal pharmacological properties. Bivalent ligands are designed to span across homo- or 
heterodimeric GPCRs and target the two receptor protomers simultaneously. An advantage of 
bivalent ligands is the increase in affinity (relative to the individual binding of each 
pharmacophore unit), which is an inherent thermodynamic feature of a cooperative binding 
system.98 In this way, the binding of the first pharmacophore facilitates the binding of the second 
pharmacophore by having it localized in the vicinity of its respective binding pocket, thereby 
significantly lowing the overall entropy of the ligand-receptor complex.98   
Significant pharmacological and therapeutic advantages have been reported for 
administration of bivalent ligands targeting µOR-δOR, µOR-CB1,  and µOR-mGlu5,  including 
enhanced antinociception compared to morphine and reduced side effects such as tolerance, 
dependence and respiratory depression.101-103 Bivalent ligands simultaneously antagonizing both 
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receptor protomers in GPCR heteromers have been found to be more efficacious on targeting 
µOR-CCR5 and µOR-κOR.104,105 Interestingly, two bivalent ligands MMG22 and MCC22, have 
been found to induce co-localized receptors (µOR, mGlu5 and CCR5) to form heteromers (µOR-
mGlu5 and µOR-CCR5 respectively) that do not occur naturally.110  Overall, the use of bivalent 
ligands has exhibited great potential in optimizing and manipulating the desired pharmacological 
and therapeutic effects.  
Homobivalent ligands have been reported for both the D2R homomer and the 2AR 
homomer. Novel bivalent ligands of the D2R homomer exhibit markedly enhanced affinity with 
EC50 in the subnanomolar or picomolar range.111,112 Two homobivalent ligands of the 
antipsychotic clozapine showed significant gains in affinity (75- and 79-fold) and activity (9- and 
5-fold) relative to the original pharmacophore, clozapine.113 M100907, a novel bivalent 
antagonist of the 2AR homomer, exhibits high affinity and potency in vitro and efficacy in 
vivo.114,115   
Heterobivalent ligands with the two pharmacophores targeting D2R and 2AR respectively 
have not been reported in literature. Considering the pharmacological advantages of bivalent 
ligands,98 the enhanced effectiveness of APDs on the function of the D2R-2AR heteromer, and 
the clinical benefits of APDs combinations,116 I propose the utility of putative D2R-2AR 
heterobivalent ligands that could antagonize D2R and 2AR simultaneously (with one 
pharmacophore unit being a typical APD moiety and the other an atypical APD moiety) (Figure 
6.4 C). I anticipate that this type of bivalent ligands would have superior advantages compared to 
normal APDs:  
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1. Such bivalent ligands would have significantly higher affinity compared to typical or 
atypical APDs, leading to enhanced improvement of schizophrenia symptoms and reduced 
application of doses.  
2. Antipsychotic effects through antagonism on 2AR of the D2R-2AR heteromer would 
reduce the side effects of typical APDs such as extrapyramidal symptoms and weight gain, 
hyperprolactinemia due to D2R antagonism.117,118   
3. Heteromerization between D2R and 2AR would be promoted upon application of the 
heterobivalent ligands. Subsequently, the potency of the two pharmacophores antagonizing D2R 
and 2AR would be potentiated through the function of the D2R-2AR heteromer.    
4. The effectiveness of each APD pharmacophore unit would be augmented through the 
functional cross-talk of the D2R-2AR heteromer.  
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Figure 6.1 Criteria to establish GPCR heteromers 
A. Criteria to establish GPCR heteromers in native tissue 
Adapted from Gomes et al., Annu. Rev. Pharmacol. Toxicol. (2016) 
B. Methods used to assess D2R-2AR heteromer in heterologous system and native tissue. 
Fulfilled criterion with established evidence are highlighted in green.  
 
 
A 
 
 
B 
 Heterologous system Native tissue 
Criterion 1 BiFC PLA in striatum 
Criterion 2 oocyte assay 
Ca assay 
fEPSP assay in PFC 
DA desensitization assay in VTA 
Criterion 3 disruptive peptide 
mutagenesis 
disruptive peptide 
AMPH model in mice 
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Figure 6.2 Aromatic residues are highly conserved at positions of 5.47, 5.48, 6.51 and 6.52 
in aminergic receptors 
Alignment of the 5.47, 5.48, 6.51 and 6.52 residues of all 44 human aminergic receptors. 
Receptors are grouped by subtype. Receptors with four conserved aromatic residues are 
highlighted in green. Receptors with solved crystal structure are highlighted in bold. Non-
conserved (non-aromatic) residues are highlighted in red.  
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Figure 6.3 The dual role of D2R-2AR in psychosis  
Schematic model showing both Gi and Gq signaling is increased in a psychotic state and through 
the functional cross-talk of D2R-2AR heteromer compared to the physiological state. Application 
of antagonist to either D2R or 2AR reverses the Gi and Gq signaling through the functional 
cross-talk of D2R-2AR.  
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Figure 6.4 Putative D2R-2AR bivalent ligand potentiating D2R-2AR heteromerization and 
antagonism on each protomer 
A. Computational model of bivalent ligand binding to the orthosteric binding sites of GPCR 
heterodimer. The two pharmacophore units (magenta) are linked by spacer (grey).  
B. The linker length is optimizable and shortest along the receptors van der walls surfaces.  
Adapted from Pérez-Benito et al., Bioinformatic (2018) 
C. Schematic model of putative bivalent ligands of D2R-2AR with one pharmacophore 
antagonizing D2R and the other antagonizing 2AR. These bivalent ligands switch the equilibrium 
between homomers, monomers and heteromers toward the heteromers and potentiate the 
antagonism on each protomer.  
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A.  MATERIALS AND METHODS 
 
A1. Molecular biology 
For expression in Xenopus oocytes, the pGEMHE vector was used for GIRK4*, PTX and 
D2R; the pXoom vector was used for 2AR and RGS2. All DNAs were human except for mouse 
D2R. Point mutations were introduced using standard Pfu-based mutagenesis techniques 
according to the QuikChange protocol (Agilent Technologies) and mutations were verified by 
sequencing (Macrogen). Plasmids were linearized and purified. In vitro transcription was 
performed using a commercially available T7 mRNA transcription kit followed by a final 
purification. 
 
A2. Drugs and chemicals 
 Dopamine hydrochloride, serotonin hydrochloride, and 2,5-Dimethoxy-4-
iodoamphetamine (DOI) hydrochloride, were purchased from Sigma. R-quinpirole 
hydrochloride, and haloperidol were purchased from Tocris. Pimavanserin was purchased from 
MedChem Express. 
 
A3. Cells and transfections 
HEK-293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen, Carlsbad, CA) supplemented with 10 % (v/v) fetal bovine serum at 37 °C in a 5 % 
CO2 humidified atmosphere. Transfections were performed using PEI according to the 
manufacturer’s instructions.  
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A4. Oocyte preparation and injection 
Oocytes from Xenopus laevis were surgically removed and subjected to collagenase 
treatment according to standard protocols. Once defolliculated, oocytes were incubated in OR2 
solution supplemented with Ca2+ and Penicillin/Streptomycin antibiotics. Stage V-VI oocytes 
were selected and injected with 50 nL of cRNA resuspended in DEPC water.  
 
A5. Two-electrode voltage clamp 
          Borosilicate glass electrodes were pulled using a Flaming-Brown micropipette puller and 
filled with a 3M KCl solution containing 1% agarose. Resistances were kept between 0.1 and 
1.0 MW. Oocyte currents were measured by two-electrode voltage clamp (TEVC) with a 
GeneClamp 500 amplifier (Axon Instruments, Union City, CA). A high-potassium (HK) solution 
(96 mM KCl, 1 mM NaCl, 1 mM MgCl2, 5 mM KOH/HEPES, pH 7.4) was used to perfuse 
cRNA-injected oocytes expressing the appropriate proteins to obtain basal currents. 3mM BaCl 
solution was used to block GIRK4* channel. Inwardly rectifying potassium currents through 
GIRK4* were obtained by clamping the cells at a voltage ramp from -80 to +80 mV.  
 
A6. Statistics 
All error bars represent the standard error of the mean (SEM). Statistical significance was 
assessed using t test (unpaired and nonparametric) in Prism. Statistical significance was set at p < 
0.05, 0.005, 0.0005 or 0.0001 denoted in figures by *, **, ***, **** asterisks, respectively. 
Unless otherwise noted, all experiments were repeated in at least two separate batches of oocytes 
or cells.  
 
